

# BEST AVAILABLE COPY

19  **Europäisches Patentamt**  
**European Patent Office**  
**Office européen des brevets**

11 Publication number:

**0 111 993**  
**A2**

12 **EUROPEAN PATENT APPLICATION**

21 Application number: 83305611.2

22 Date of filing: 22.09.83

51 Int. Cl.<sup>3</sup>: **C 07 D 235/30**

**C 07 D 235/06, C 07 D 235/28**  
**C 07 D 235/26, C 07 D 235/12**  
**C 07 D 401/04, C 07 D 417/04**  
**A 61 K 31/415, A 61 K 31/425**  
**A 61 K 31/44**

30 Priority: 27.09.82 US 424784

43 Date of publication of application:  
27.06.84 Bulletin 84/26

84 Designated Contracting States:  
AT BE CH DE FR GB IT LI LU NL SE

71 Applicant: **ELI LILLY AND COMPANY**  
307, East McCarty Street  
Indianapolis Indiana 46285(US)

72 Inventor: **Spitzer, Wayne Alfred**  
5501 Moller Road  
Indianapolis Indiana 46254(US)

74 Representative: **Crowther, Terence Roger et al,**  
Erl Wood Manor  
Windlesham Surrey GU20 6PH(GB)

54 Improvements in or relating to benzimidazoles.

57 Certain N-substituted benzimidazoles, which are potent antiviral agents, are disclosed. The compounds are prepared by reacting the corresponding keto derivative with an alkylating agent or by cyclizing the corresponding o-phenylenediamine. Pharmaceutical formulations containing such compounds and a method of treating viral infections are provided.

89+ EP 0 111 993 A2

21

## IMPROVEMENTS IN OR RELATING TO BENZIMIDAZOLES

5 The incidence of viral upper respiratory disease is immense. It has been estimated that nearly a billion cases annually appear in the United States alone. Studies performed in England [Tyrell and Bynoe, Lancet 1, 76 (1966)] indicated that 74 percent of persons having colds were infected with rhinoviruses. Because more than 80 strains of rhinoviruses are already identified, the development of a practical  
10 rhinovirus vaccine is not feasible, and chemotherapy appears to be the more desirable approach.

The ability of chemical compounds to suppress the growth of viruses in vitro is readily demonstrated by using a virus plaque suppression test similar to  
15 that described by Siminoff, Applied Microbiology, 9(1), 66 (1961).

Certain benzimidazole compounds have been found to possess anti-viral activity, including those compounds found in the following U.S. Patents: 4,150,028,  
20 4,216,313, 4,293,558, and 4,338,315 (1-thiazoliny1 and -thiaziny1 keto benzimidazoles); 4,174,454 (alkyldeny1methyl-substituted-1-sulfonylbenzimidazoles); 4,018,790, 4,118,573, 4,196,125, 4,243,813 and 4,316,021 (1-sulfonyl-2,5(6)-substituted benzimidazoles);  
25 4,008,243 (1-thiazoliny1 and -thiaziny1 benzimidazole esters); 4,230,868 ( $\alpha$ -alkyl- $\alpha$ -hydroxybenzy1-substituted-1-sulfonylbenzimidazoles); and 4,118,742, 4,289,782, and 4,338,329 (carbonyl substituted-1-sulfonylbenzimidazoles).  
30




X-5513

-2-

This invention is directed to novel benzimidazole compounds which inhibit the growth of viruses, particularly rhinoviruses, polio viruses, Coxsackie viruses, echo virus, and Mengo virus.

5 This invention concerns pharmacologically useful benzimidazole compounds having the formula



wherein:

15  $R_1$  is  $C_1-C_8$  alkyl,  $C_2-C_8$  alkenyl,  $C_3-C_7$  cycloalkyl,  $C_5-C_7$  cycloalken-1-yl, 2-pyridyl, 2-thiazolyl, adamantyl, hydroxy-substituted  $C_1-C_8$  alkyl, unsubstituted or substituted phenyl, unsubstituted or substituted benzyl, or  $R_4R_5NCH_2-$ , where  $R_4$  and  $R_5$  are independently  $C_1-C_3$  alkyl or  $R_4$  and  $R_5$ , when taken together with the nitrogen atom to which they are attached, are pyrrolidino, piperidino, or morpholino;

20  $R_2$  is hydrogen, amino,  $C_1-C_4$  alkylamino, methylmercapto, hydroxy,  $C_1-C_4$  acylamino, or 1-hydroxyethyl;

25  $R_3$  is  $C_2-C_8$  alkanoyloxy, unsubstituted or substituted phenylacetoxo, unsubstituted or substituted benzoyloxy, or  $R_6C-\underset{Z}{\overset{||}{O}}$ ;

30


X-5513

-3-

5        Z is oxygen, hydroxyimino,  $C_1-C_4$  alkoxyimino,  
 $C_1-C_4$  acyloxyimino, hydrazono,  $C_1-C_7$  alkylidene,  
 $=CHBr$ ,  $=CHCl$ ,  $=CBr_2$ ,  $=CCl_2$ ,  $=CBrCl$ ,  $=CHCN$ ,  $=CHCONH_2$ ,  
 or  $=CHCO_2(C_1-C_4 \text{ alkyl})$ ;  
 $R_6$  is  $C_1-C_7$  alkyl,  $C_3-C_7$  cycloalkyl,  $(C_3-C_7$   
 cycloalkyl)methyl, 2- $(C_3-C_7$  cycloalkyl)ethyl,  
 unsubstituted or substituted benzyl, unsubstituted  
 or substituted phenyl; and  
 10         $R_3$  is at the 5 or 6 position,  
 subject to the limitation that when  $R_2$  is hydroxy,  
 $R_1$  may only be  $C_5-C_7$  1-cycloalkenyl; and pharmaceu-  
 tically acceptable salts thereof.

15        The compounds of formula I are prepared  
 by a process which comprises:

(A) alkylating a benzimidazole compound  
 of the formula



25        wherein  $R_3$  is defined as above and  $R_2$  is other than  
 hydroxy or amino, with a compound of the formula  $R_1X$   
 where  $R_1$  is defined as above and X is fluoro, chloro,  
 bromo, or iodo, to provide the compounds of formula I  
 where  $R_2$  is other than hydroxy or amino; or


30

BAD ORIGINAL

X-5513


-4-

(B) heating a compound of the formula




10 wherein  $R_1$  and  $R_3$  are defined as above, with formic acid or lactic acid, preferably in the presence of a mineral acid, to provide the compounds of formula I wherein  $R_2$  is hydrogen or 1-hydroxyethyl; or

(C) cyclizing a compound of the formula



20 wherein  $R_1$  and  $R_3$  are defined as above, with cyanogen halide, to provide the compounds of formula I wherein  $R_2$  is amino; or

(D) alkylating a benzimidazole compound of the formula




X-5513

-5-


wherein  $R_1$  and  $R_3$  are defined as above, with a  $C_1$ - $C_4$  alkyl halide, to provide the compounds of formula I wherein  $R_2$  is  $C_1$ - $C_4$  alkylamino; or

5 (E) alkylating a benzimidazole compound of the formula



wherein  $R_1$  and  $R_3$  are defined as above, with methyl halide in the presence of a weak base, to provide the compounds of formula I wherein  $R_2$  is methylmercapto; 15 or

(F) acylating a benzimidazole compound of the formula



25 wherein  $R_1$  and  $R_3$  are defined as above, with a  $C_2$ - $C_4$  anhydride, a mixed anhydride of formic and acetic anhydride, or a  $C_1$ - $C_4$  acyl halide, to provide the compounds of formula I wherein  $R_2$  is  $C_1$ - $C_4$  acylamino; or


30

X-5513

-6-

(G) reacting a benzimidazole compound of the formula


5



wherein  $R_2$  and  $R_3$  are defined as above, with  $R_4R_5NH$ ,  
 10 where  $R_4$  and  $R_5$  are defined as above, and formaldehyde,  
 to provide the compounds of formula I wherein  $R_1$  is  
 $R_4R_5NCH_2-$ ; or


(H) condensing a compound of the formula

15



20 wherein  $R_1$  and  $R_3$  are defined as above, with a  $\beta$ -keto  
 ester of the formula

25




wherein  $n$  is 0-2, to provide the compounds of formula I  
 wherein  $R_2$  is hydrogen and  $R_1$  is  $C_5-C_7$  cycloalken-1-yl;  
 30 or

X-5513


-7-

(I) esterifying a benzimidazole compound  
of the formula



wherein  $R_1$  is defined as above, and  $R_2$  does not contain  
10 a hydroxy group, with an anhydride or acyl halide, to  
provide the compounds of formula I wherein  $R_3$  is  $C_2-C_8$   
alkanoyloxy, unsubstituted or substituted phenylacetoxy,  
or unsubstituted or substituted benzoyloxy; or

(J) reacting a benzimidazole compound of  
15 the formula



wherein  $R_1$ ,  $R_2$  and  $R_6$  are defined as above, with  
hydroxylamine, or its hydrochloride salt, hydrazine or  
 $C_1-C_4$  alkoxyamine, to provide the compounds of formula I  
25 wherein Z is hydroxyimino, hydrazono, or  $C_1-C_4$  alkoxy-  
imino; or

30

BAD ORIGINAL



X-5513


-8-

(K) acylating a compound of formula I wherein Z is hydroxyimino with a  $C_1-C_4$  anhydride or a  $C_1-C_4$  acyl halide, to provide the compounds of formula I wherein Z is  $C_1-C_4$  acyloxyimino; or

5 (L) etherifying a compound of formula I wherein Z is hydroxyimino with a  $C_1-C_4$  alkyl halide, or alkylating the compound of formula I where  $R_3$  is  $R_6-C(=O)-$  with a  $C_1-C_4$  alkoxyamine, to provide the com-  
10 pounds of formula I wherein Z is  $C_1-C_4$  alkoxyimino; or

(M) dehydrating a benzimidazole compound of the formula

15



20


wherein  $R_1$ ,  $R_2$  and  $R_6$  are defined as above, and one of  $R_7$  and  $R_8$  is hydrogen and the other of  $R_7$  and  $R_8$  is hydrogen,  $C_1-C_6$  alkyl,  $-CN$ ,  $-CONH_2$ , or  $-CO_2-(C_1-C_4$  alkyl), with an acid, to provide the compounds of  
25 formula I wherein Z is  $C_1-C_7$  alkylidene,  $=CHCN$ ,  $=CHCONH_2$ , or  $=CHCO_2(C_1-C_4$  alkyl); or

30

X-5513

-9-

(N) reacting a benzimidazole compound of the formula



wherein  $R_1$ ,  $R_2$  and  $R_6$  are defined as above, with a halogenating agent, to provide the compounds of formula I wherein Z is =CHBr, =CHCl, =CBr<sub>2</sub>, =CCl<sub>2</sub>, or =CBrCl; or

(O) resolving the benzimidazole compounds of formula I into its 5 and 6 isomers; or

15 (P) resolving the benzimidazole compounds of formula I wherein Z is hydroxyimino, C<sub>1</sub>-C<sub>4</sub> alkoxyimino, C<sub>1</sub>-C<sub>4</sub> acyloxyimino, or hydrazono into its syn and anti isomers; or

20 (Q) resolving the benzimidazole compounds of formula I wherein Z is C<sub>1</sub>-C<sub>7</sub> alkylidene, =CHBr, =CHCl, =CBr<sub>2</sub>, =CCl<sub>2</sub>, =CBrCl, =CHCN, =CHCONH<sub>2</sub> or =CHCO<sub>2</sub>(C<sub>1</sub>-C<sub>4</sub> alkyl) into its cis and trans isomers; or

(R) salifying the compounds of formula I to form pharmaceutically acceptable salts.

25 This invention additionally provides a method for controlling the growth of viruses which comprises administering to a warm-blooded mammal an effective antiviral amount of a benzimidazole derivative of formula I, or a pharmaceutically acceptable salt thereof.

30 A further embodiment of the present invention includes a pharmaceutical formulation comprising as an active ingredient a benzimidazole derivative of formula I,

BAD ORIGINAL

X-5513

-10-

or a pharmaceutically acceptable acid addition salt thereof, associated with one or more pharmaceutically acceptable carriers.

5 The present invention relates to new benzimidazole compounds of formula I that are potent antiviral agents and that are accordingly useful in the treatment and control of viral growth, including growth attributable to rhinovirus, polio, coxsackie, echo virus, mengo virus, influenza, and related viral  
10 growths.

A preferred group of compounds are the compounds of formula (I) wherein:

$R_1$  is  $C_1-C_8$  alkyl,  $C_2-C_8$  alkenyl, phenyl, substituted phenyl, or  $C_3-C_7$  cycloalkyl;  
15  $R_2$  is hydrogen or amino; and  
 $R_3$  is  $R_6C-\underset{\underset{Z}{\parallel}}{\quad}$  wherein  $R_6$  is phenyl or substituted phenyl.

Especially preferred compounds of formula (I)  
20 are those wherein:

$R_1$  is isopropyl, cyclohexyl or phenyl;  
 $R_2$  is hydrogen or amino; and  
 $R_3$  is  $R_6C-\underset{\underset{Z}{\parallel}}{\quad}$  wherein  $R_6$  is phenyl and Z is oxygen,  
25 hydroxyimino,  $=CHBr$ ,  $=CHCN$ ,  $=CHCH_3$ , or  $=CHCONH_2$ .

Especially preferred compounds are those of formula I wherein  $R_3$  is at the 6 position.

30 Illustrative of the compounds provided by formula I are the following:

1-isopropyl-2-amino-5(6)-acetylbenzimidazole,  
1-cyclopentyl-2-acetamido-5(6)-propionylbenzimidazole,



X-5513

-11-

- 1-butyl-2-formamido-5(6)-(1-hydroxyazonoctyl)-  
benzimidazole,  
1-dimethylaminomethyl-2-methylmercapto-5(6)-  
[( $\alpha$ -butoxyimino)cycloheptylmethyl]benzimidazole,  
1-morpholinylmethyl-5(6)-hydroxybenzimidazole,  
5 1-piperidinylmethyl-2-formamido-5(6)-  
heptanoyloxybenzimidazole,  
1-(N-methyl-N-propylaminomethyl)-2-butylamino-  
5(6)-(4-chlorobenzoyloxy)benzimidazole,  
1-phenyl-2-propionamido-5(6)-[(1-methoxyimino-  
10 2-cyclopentyl)ethyl]benzimidazole,  
1-(2-thiazolyl)-2-acetamido-5(6)-(3,4-  
dichlorobenzoyl)benzimidazole,  
1-diisopropylaminomethyl-2-(1-hydroxyethyl)-  
5(6)-[ $\alpha$ -pentylidenebenzyl]benzimidazole,  
15 1-cyclobutyl-2-propionamido-5(6)-hydroxy-  
benzimidazole,  
1-octyl-5(6)-phenylacetoxymethylbenzimidazole,  
1-piperidinylmethyl-2-methylmercapto-5(6)-  
( $\alpha$ -ethoxyiminocyclopentylmethyl)benzimidazole,  
20 1-pentyl-2-acetamido-5(6)-heptanoylbenzimid-  
azole,  
1-(1-cyclopentenyl)-2-hydroxy-5(6)-( $\alpha$ -  
hydrazonocyclopentylmethyl)benzimidazole,  
1-cyclohexyl-2-amino-5(6)-(4-methoxybenzoyl-  
25 oxy)benzimidazole,  
1-(4-methoxyphenyl)-5(6)-( $\alpha$ -hexylidenebenzyl)-  
benzimidazole,  
1-(1-adamantyl)-2-formamido-5(6)-(3-cyclo-  
pentylpropionyl)benzimidazole,  
30 1-diethylaminomethyl-2-acetamido-5(6)-(1-  
ethoxyiminohexyl)benzimidazole,

RAD ORIGINAL

X-5513-

-12-


- 1-ethyl-2-ethylamino-5(6)-[1-(4-fluorophenyl)-  
2-cyanoethenyl]benzimidazole,
- 1-(N-ethyl-N-propylaminomethyl)-2-methylmer-  
capto-5(6)-(α-n-butanoyloxyiminobenzyl)benzimidazole,
- 5 1-(morpholinylmethyl-2-(1-hydroxyethyl)-  
5(6)-(1-phenyl-2-bromoethenyl)benzimidazole,
- 1-allyl-2-isopropylamino-5(6)-[1-(2,4,6-  
trimethylphenyl)heptylenyl]benzimidazole,
- 1-dipropylaminomethyl-2-acetamido-5(6)-(4-  
10 trifluoromethylbenzoyl)benzimidazole,
- 1-isopropyl-5(6)-(α-methoxyimino-3,4-di-  
chlorobenzyl)benzimidazole,
- 1-(N-methyl-N-ethylaminomethyl)-2-amino-5(6)-  
(α-propoxyimino-2-iodo-4-butoxybenzyl)benzimidazole,
- 15 1-(1-cycloheptenyl)-2-hydroxy-5(6)-propionyl-  
oxybenzimidazole,
- 1-methyl-2-methylmercapto-5(6)-(α-hydrazono-  
3-butoxybenzyl)benzimidazole,
- 1-cyclopropyl-2-amino-5(6)-(4-butylbenzoyl)-  
20 benzimidazole,
- 1-(2-pyridyl)-5(6)-(3-chloro-4-methoxybenzoyl)-  
benzimidazole,
- 1-(2-thiazolyl)-2-ethylamino-5(6)-hydroxy-  
benzimidazole,
- 25 1-t-butyl-2-(1-hydroxyethyl)-5(6)-(α-hydroxy-  
imino-3-methoxybenzyl)benzimidazole,
- 1-benzyl-5(6)-(α-hydroxyimino-3-bromo-4-  
ethoxybenzyl)benzimidazole,
- 1-(3,5-dimethoxyphenyl)-2-amino-5(6)-penta-  
30 noyloxybenzimidazole, and
- 1-hexyl-2-formamido-5(6)-[(1-hydroxyimino-2-  
cyclobutyl)ethyl]benzimidazole.

X-5513

-13-

The compounds of formula I are prepared, according to part (A) above, by reacting a tautomeric benzimidazole compound of the formula

5




with a halo compound having the formula  $R_1X$  wherein  $R_1$ ,  $R_2$  and  $R_3$  are as defined hereinabove, and X is fluoro, chloro, bromo, or iodo.

10

Alternatively, the compounds may be prepared according to the following scheme:

15

SCHEME I



20

25

wherein  $R_1$ ,  $R_3$ , and X are the same as described hereinabove and  $R_3$  is at the 4 or 5 position of III, IV, and V. The last step of Scheme I is shown by part (B), (C) or (H) above.

30

The term "tautomeric benzimidazole" refers to a benzimidazole reagent which can be substituted at either nitrogen atom with a hydrogen atom. The benzimidazole reactant, unsubstituted on nitrogen and bearing a substituent group at the 5 position of the benzene moiety, has a corresponding tautomeric form wherein the substituent resides alternatively at the 6 position. The isomer mixture can be indicated by numbering the alternate positions as 5(6). As a consequence of such tautomerism, the reaction of a 5(6)-substituted N-unsubstituted benzimidazole with  $R_1X$  produces isomeric mixtures of 5(6)-substituted N-substituted benzimidazoles.

The term " $C_1-C_8$  alkyl" refers to the straight and branched aliphatic radicals of one to eight carbon atoms including methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, amyl, isoamyl, sec-amyl, sec-isoamyl (1,2-dimethylpropyl), tert-amyl (1,1-dimethylpropyl), hexyl, isohexyl, (4-methylpentyl), sec-hexyl (1-methylpentyl), 2-methylpentyl, 3-methylpentyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 3,3-dimethylbutyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl, 1,2,2-trimethylpropyl, 1,1,2-trimethylpropyl, heptyl, isoheptyl (5-methylhexyl), sec-heptyl (1-methylhexyl), 2,2-dimethylpentyl, 3,3-dimethylpentyl, 4,4-dimethylpentyl, 1,2-dimethylpentyl, 1,3-dimethylpentyl, 1,4-dimethylpentyl, 1,2,3-trimethylbutyl, 1,1,2-trimethylbutyl, 1,1,3-trimethylbutyl, octyl, isooctyl (6-methylheptyl), sec-octyl (1-methylheptyl), tert-octyl (1,1,3,3-tetramethylbutyl), and the like.

The term  $C_1-C_8$  alkyl includes within its definition the terms " $C_1-C_3$  alkyl," " $C_1-C_4$  alkyl," " $C_1-C_5$  alkyl," " $C_1-C_6$  alkyl", and " $C_1-C_7$  alkyl."

5       The term " $C_3-C_7$  cycloalkyl" refers to the saturated alicyclic rings of three to seven carbon atoms such as cyclopropyl, methylcyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, 1-, 2-, 3- or 4-methylcyclohexyl, cycloheptyl, and the like. The term " $(C_3-C_7$  cycloalkyl)methyl" refers to a methyl radical  
10 substituted with saturated alicyclic rings of three to seven carbon atoms as exemplified in the term " $C_3-C_7$  cycloalkyl," such as cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethyl, cycloheptylmethyl and the like. The term "2- $(C_3-C_7$  cycloalkyl)ethyl" refers to ethyl radicals substituted on  
15 the carbon atom in the 2 position with saturated alicyclic rings of three to seven carbon atoms.

      The term " $C_5-C_7$  cycloalken-1-yl" refers to alicyclic rings of five to seven carbon atoms which  
20 have a double bond in the 1-position, such as cyclopenten-1-yl, cyclohexen-1-yl, 2-, 3-, or 4-methylcyclohexen-1-yl, cyclohepten-1-yl, and the like.

      The term " $C_2-C_8$  alkanoyl" refers to the straight and branched aliphatic acyl radicals of two  
25 to eight carbon atoms such as acetyl, propionyl, butyryl, 2-methylpropionyl, pentanoyl, hexanoyl, heptanoyl, octanoyl, and the like.

      The term " $C_1-C_7$  alkylidene" refers to straight and branched alkylidene radicals of one to  
30 seven carbon atoms such as methylene, ethylidene,



propylidene, isopropylidene, butylidene, isobutylidene, 3-methylbutylidene, n-hexylidene and the like.

The term " $C_1$ - $C_4$  alkoxy" includes the straight and branched aliphatic ether radicals of one to four  
5 carbon atoms such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, and the like. The term " $C_1$ - $C_4$  alkoxyimino" refers to the O-aliphatic hydroxyimine radical of one to four carbon atoms derived from hydroxylamine. Methoxyamine hydrochloride  
10 is available from commercial sources. Other hydroxylamine derivatives are available by alkylation of acetone oxime by  $C_1$ - $C_4$  alkyl halides followed by acid hydrolysis.

The term "substituted" -phenyl, -benzyl, -phenylacetoxy, and -benzoyloxy refers to those groups  
15 substituted on the aromatic ring with one to three of  $C_1$ - $C_4$  alkyl,  $C_1$ - $C_4$  alkoxy, fluoro, chloro, bromo, iodo, nitro, amino, or trifluoromethyl. The preferred substituent is that in the 4' or para position of the  
20 aromatic ring, especially 4'-methoxy.

In the reaction of a tautomeric benzimidazole II with  $R_1X$ , the preferred reactants are benzimidazoles bearing 5(6)-substituents which will not react with  $R_1X$  under the reaction conditions. The benzimidazole II  
25 and  $R_1X$  are normally employed in approximately equimolar quantities, although an excess of either can be used if desired. The reaction can be carried out in any number of unreactive solvents, including acetone, tetrahydrofuran (THF), tertiary amides such as N,N-  
30 dimethylformamide (DMF), and chlorinated hydrocarbons

X-5513

-17-

such as dichloromethane, dichloroethane and chloroform. The reaction medium may also contain added base to serve as an acid-binding agent. Some examples of suitable bases for this purpose are pyridine, triethyl-  
5 amine, N-methylmorpholine, sodium bicarbonate, and sodium hydride. A preferred solvent medium for the reaction is DMF containing sodium hydride as a base.

The reaction is best carried out at a temperature between 0°C. and the reflux temperature of the  
10 solvent system employed. Preferably, the reaction is carried out at 0°C. to room temperature. In this temperature range, the reaction is substantially complete within 1 to 48 hours.

The product of the reaction is a 1-substituted benzimidazole of formula I, hereinafter called  
15 the benzimidazole compound. The product may be isolated by filtering the reaction mixture and concentrating the filtrate to induce crystallization. Alternatively, the reaction mixture can be evaporated  
20 to dryness and the residue treated with a suitable solvent such as acetone or methanol to separate and remove any insoluble material. The solution containing the benzimidazole compound is concentrated to crystallize the product or it is evaporated to give a second  
25 residue, which is dissolved in methanol, for example. The benzimidazole compound is recovered from the methanol by crystallization. Chromatography over silica gel may also be employed in the purification scheme, either alone or in combination with the above  
30 purification steps.


X-5513

-18-

The reaction of the tautomeric benzimidazole II and  $R_1X$  generally provides an approximate 1:1 mixture of 5- and 6-substituted benzimidazole compounds. The isomers are separable by fractional crystallization or by chromatography, as shown by part (O) above.

The 5(6)-ketobenzimidazole compounds I wherein  $R_3$  is  $R_6CO$  can be prepared from the corresponding 5(6)-ketobenzimidazoles II by reaction with  $R_1X$ . The ketobenzimidazole reactant II can be prepared from the appropriate keto *o*-phenylenediamine by methods known to the benzimidazole art. U.S. Patent No. 3,657,267 discloses the preparation of keto *o*-phenylenediamines of the formula

15



wherein  $R_6$  is lower alkyl, cycloalkyl, phenyl or phenyl substituted by halogen, lower alkyl or lower alkoxy. The method of preparation involves the ammonolysis and reduction of a 4-halo-3-nitrophenyl ketone which is prepared by the Friedel-Crafts reaction of either (1) a 4-halo-3-nitrobenzoyl chloride with an appropriate hydrocarbon or (2) a halobenzene with an appropriate acid chloride followed by aromatic nitration. Such methods make available the required keto *o*-phenylenediamines wherein  $R_6$  in the formula above is additionally  $C_3$ - $C_7$  cycloalkyl, ( $C_3$ - $C_7$  cycloalkyl)methyl,

30

X-5513


-19-

2-(C<sub>3</sub>-C<sub>7</sub> cycloalkyl)ethyl or benzyl. Alternatively, the ketobenzimidazole reactants can be prepared from acetanilide by a Friedel-Crafts acylation with the appropriate derivative of a C<sub>2</sub>-C<sub>8</sub> alkanolic acid, C<sub>3</sub>-C<sub>7</sub> cycloalkyl carboxylic acid, C<sub>3</sub>-C<sub>7</sub> cycloalkylacetic acid, 3-(C<sub>3</sub>-C<sub>7</sub> cycloalkyl)propionic acid, phenylacetic acid, benzoic acid or substituted benzoic acid. The resulting 4-ketoacetanilide is nitrated to give a 2-nitro-4-ketoacetanilide. The acetanilide is hydrolyzed to give a 2-nitro-4-ketoaniline. The nitroaniline is catalytically hydrogenated to yield a 4-keto-o-phenylenediamine which is ring closed to provide the appropriate 5(6)-ketobenzimidazole. The following embodiment illustrates in principle the preparation of a 5(6)-ketobenzimidazole compound. 4-Propionylacetanilide is nitrated at 0°C. to yield 2-nitro-4-propionylacetanilide. The acetanilide is hydrolyzed and catalytically hydrogenated to give 4-propionyl-o-phenylenediamine. The phenylenediamine is reacted with cyanogen bromide to give 2-amino-5(6)-propionylbenzimidazole. The propionylbenzimidazole is reacted with isopropyl bromide to provide 1-isopropyl-2-amino-5(6)-propionylbenzimidazole. These methods make available the 5(6)-(C<sub>2</sub>-C<sub>8</sub>)alkanoyl, 5(6)-(C<sub>3</sub>-C<sub>7</sub>)cycloalkylcarbonyl, 5(6)-(C<sub>3</sub>-C<sub>7</sub>)cycloalkylacetyl, 5(6)-[3-(C<sub>3</sub>-C<sub>7</sub> cycloalkyl)propionyl], 5(6)-phenylacetyl, 5(6)-benzoyl or the 5(6)-substituted-benzoylbenzimidazole compounds. The 5(6)-ketobenzimidazole compounds are represented by the formula

30


X-5513

-20-



wherein  $R_6$  is  $C_1$ - $C_7$  alkyl,  $C_3$ - $C_7$  cycloalkyl, ( $C_3$ - $C_7$  cycloalkyl)methyl, 2-( $C_3$ - $C_7$  cycloalkyl)ethyl, benzyl, substituted benzyl, phenyl or substituted phenyl, and  $R_1$  and  $R_2$  are as defined previously.

The intermediate benzimidazole compounds wherein  $R_3$  is hydroxy of the formula



20 wherein  $R_1$  and  $R_2$  are defined as above, can be prepared from the corresponding 5(6)-hydroxybenzimidazole reactants. The preparation of the required hydroxybenzimidazole compounds begins with the reduction of 4-methoxy-2-nitroaniline to the corresponding 4-methoxy-o-phenylenediamine. The phenylenediamine is ring closed to provide a 5(6)-methoxybenzimidazole by methods known to the benzimidazole art. The methyl ether is cleaved with hydrobromic acid to give a 5(6)-hydroxybenzimidazole. The hydroxybenzimidazole is reacted

25

30

X-5513

-21-

with the appropriate  $R_1X$  to provide the required 1-substituted-5(6)-hydroxybenzimidazole compounds.

The phenolic hydroxyl functionality of the 5(6)-hydroxybenzimidazole compounds can be reacted by part (I) above with the anhydrides or halides, such as chlorides of  $C_2-C_8$  alkanolic acids, phenylacetic acids or benzoic acids in an aprotic solvent to provide the corresponding esters. The ester products derived from the 5(6)-hydroxybenzimidazole reactants are respectively the 5(6)-( $C_2-C_8$ )alkanoyloxy-, 5(6)-phenylacetoxy-, or 5(6)-benzoyloxy-benzimidazole compounds. Alternatively the hydroxybenzimidazole compounds can be esterified with the appropriate acid reactant in the presence of 1,1'-carbonyldiimidazole in dimethylformamide.


The benzimidazole compounds which are required as starting materials in the foregoing process can be prepared according to a variety of methods known to the benzimidazole art. The preparation of a variety of benzimidazoles is well documented in Weissberger's The Chemistry of Heterocyclic Compounds, Imidazole and Its Derivatives, Interscience Publishers Co., New York., 1953. The 2-aminobenzimidazoles of formula I can be prepared by part (C) above by cyclizing the appropriate *o*-phenylenediamines with cyanogen halide, for example cyanogen bromide, as described by Buttle, et al., Bio. Chem. J., 32, 1101 (1938) and British Pat. 551,524. See also U.S. Patent No. 4,118,742, Example 29(A). Acylation of the 2-aminobenzimidazole reactant of the formula

30

X-5513

-22-

5



wherein  $R_1$  and  $R_3$  are defined as before, by part (F) above, with acetic, propionic, or butyric anhydride provides the respective 2-acetamido, 2-propionamido, or 2-butynamido benzimidazoles. The 2-formamidobenzimidazole reagents can be obtained by reacting the appropriate 2-aminobenzimidazole with the mixed anhydride obtained from formic acid and acetic anhydride. Alternatively, the 2-acylamino benzimidazole compounds can be prepared from the corresponding 2-aminobenzimidazole compounds by acylation with the appropriate acyl halide as described hereinabove.

The 2-unsubstituted benzimidazoles ( $I$ ,  $R_2$  is hydrogen) are prepared by heating the appropriate o-phenylenediamine of formula V, by part (B) above, with formic acid, usually in the presence of a mineral acid, such as hydrochloric acid. The 2-(1-hydroxyethyl) substituted benzimidazoles are similarly prepared using lactic acid instead of formic acid.


In the preparation of the preferred compounds where  $R_6$  is phenyl or substituted phenyl, a preferred route of synthesis consists of the Friedel-Crafts acylation of 3,4-dinitrobenzoyl chloride upon the appropriately substituted benzene. The resulting 3,4-

X-5513

-23-


dinitrobenzophenone is then chemically or catalytically reduced to the corresponding 3,4-diaminobenzophenone which is then ring closed in the usual way.

The 2-methylmercaptobenzimidazoles of formula I are prepared by part (E) above, by treating the respective 2-thiobenzimidazole of the formula



wherein  $R_1$  and  $R_3$  are defined as above, with methyl-halide, e.g. methyl iodide, in the presence of a weak base. The 2-thio compounds of formula IC are prepared by heating the appropriate *o*-phenylenediamine with potassium ethyl xanthate in the usual manner.

The compounds of formula I wherein  $R_2$  is hydroxy are prepared by condensing the appropriate *o*-phenylenediamine of formula V, by part (H) above, with a  $\beta$ -keto ester of formula



where  $n$  is 0-2, according to the method summarized in Chemical Reviews, 74 (3), 384 (1974), resulting both in ring closure to the 2-hydroxy benzimidazole and substi-


30



X-5513

-24-

tution on the nitrogen atom with a  $C_5-C_7$  cycloalkenyl substituent. Both 5- and 6-isomers are formed. The 2-hydroxy benzimidazole exists with its tautomer represented by the formula



15 Additionally, N-substituted 5(6)-benzimidazoles may be prepared by the reaction of  $R_1X$  with the appropriate o-phenylenediamine followed by ring closure in the usual manner.

20 All of the above procedures result in the preparation of isomeric mixtures of the 5- and 6-substituted benzimidazoles of formula I. The mixture may be separated into the individual isomers, by part (O) above, if desired, by chromatography and/or by fractional crystallization. Since the 6-isomer is usually preferred, a regiospecific synthesis is desirable to eliminate the extra purification steps and loss of half of the material as the undesired isomer. Such a procedure is outlined in Scheme I, hereinabove.

25 The o-nitrohalobenzene derivative III is reacted with  $R_1NH_2$  at a temperature of 100-200°C. to provide the corresponding aniline IV. For a volatile amine, the general procedure involves the reaction of  
30 the amine in a solvent, such as methanol, and heating

X-5513

-25-

in a stainless steel autoclave at about 140-150°C. for about 16 hours. For non-volatile or aromatic amines, equal equivalents of III and  $R_1NH_2$  are heated with anhydrous sodium carbonate in a high boiling non-reactive solvent, such as sulfolane. Heating for 3-4 hours at 100-200°C. is usually adequate to give good yields of IV. When aromatic amines are used, a temperature range of 180-200°C. is preferred.

The aniline IV is converted to diamine V by the usual methods of chemical or catalytic reduction. Preferably, the reduction is done through catalytic hydrogenation, in a non-reactive solvent such as tetrahydrofuran, in the presence of a catalyst, such as Raney nickel.

The diamine V is then ring closed to the desired benzimidazole I in the manner previously described giving the single 5- or 6-isomer.

The required starting materials above, including  $R_1X$ ,  $R_1NH_2$ , and III, are either commercially available or may be prepared by methods known in the literature. In the preferred case wherein  $R_3$  is  $Z=C(R_6)-$  and  $R_6$  is a phenyl derivative, the preferred method of preparing compounds of formula III is the condensation of a phenyl acetonitrile with *o*-nitrochlorobenzene to give the intermediate 4-(phenylcyano-methylene)-2-chlorocyclohexa-2,5-diene-1-one oxime which upon oxidation with basic hydrogen peroxide gives III (X is chloro). The latter sequence was reported by Davis *et al.*, *J. Org. Chem.*, **26**, 4270 (1961) and Davis *et al.*, *J. Am. Chem. Soc.*, **82**, 2913 (1960).

X-5513

-26-

Dialkylaminomethyl substituents can be introduced into the benzimidazoles, by part (G) above, by means of the Mannich reaction. The N-unsubstituted benzimidazole is allowed to react with the appropriate dialkylamine in the presence of formaldehyde to produce the desired N-(dialkylaminomethyl) derivatives of formula I. If such derivatives are desired, the reaction is usually performed at the end of the synthesis because subsequent reaction steps, such as oxime formation, may remove the dialkylaminomethyl functionality.

Hydroxyimino derivatives can be prepared from the corresponding keto compounds of formula IA, by part (J) above, by treatment with hydroxylamine in the usual manner. Similarly, the hydrazono derivatives can be prepared from the keto compounds by reacting with hydrazine.

The compounds of formula I, wherein  $R_3$  is  $Z=C(R_6)-$  and Z is an acyloxyimine, are prepared, by part (K) above, by reacting the corresponding hydroxyiminobenzimidazole with the appropriate acylating agent (such as an anhydride or acyl halide).

The compounds of formula I wherein  $R_3$  is  $Z=C(R_6)-$  and Z is an alkoxyimine are prepared, by part (L) above, by reacting the appropriate keto-benzimidazole of formula IA with an alkoxyamine, or by alkylating the corresponding hydroxyiminobenzimidazole (suitable alkylating agents are an alkali metal alkoxide and alkyl halide).


30

X-5513

-27-

When the oximes and oxime derivatives are prepared, the products are usually mixtures of the syn and anti isomers. The proportion of the anti isomer can be increased by conventional methods, part (P) above, e.g. fractional crystallization or high pressure chromatography. As the anti isomer is usually more active biologically, this enrichment process is useful.

The compounds of formula I wherein  $R_3$  is  $Z=C(R_6)-$  and  $Z$  is  $C_1-C_7$  alkylidene,  $=CHCN$ ,  $=CHCONH_2$ , and  $=CHCO_2(C_1-C_4 \text{ alkyl})$  are formed by the dehydration of the corresponding carbinol, see part (M) above. Such dehydration reaction of a benzimidazole carbinol is depicted by the following generalized scheme:



wherein  $R_1$ ,  $R_2$  and  $R_6$  have the above-defined meanings, one of  $R_7$  and  $R_8$  is hydrogen and the other of  $R_7$  and  $R_8$  is hydrogen,  $C_1-C_6$  alkyl,  $-CN$ ,  $-CONH_2$ , or  $-CO_2-$  ( $C_1-C_4$  alkyl).

25 The dehydration of a benzimidazole carbinol according to the above scheme is accomplished by reaction of the carbinol with any of a number of dehydrating agents which are capable of removing a mole of water from each mole of carbinol to thus provide the  
30 corresponding olefinic benzimidazole of formula I.


X-5513

-28-

Typical dehydrating agents commonly used include acids such as sulfuric acid, hydrochloric acid, formic acid, polyphosphoric acid and p-toluenesulfonic acid. In a routine dehydration reaction, a carbinol is combined  
5 with about an equal weight amount or an excess of a dehydrating agent. The reaction normally is carried out in an organic solvent such as formic acid, chloroform, benzene, dichloromethane, or the like, at a temperature of about 20°C. to the reflux temperature of  
10 the particular solvent utilized for the reaction. Under these conditions, the dehydration typically is substantially complete within about one to about forty-eight hours. Longer reaction periods may be employed if desired. The reaction takes place in approximately  
15 two hours when the preferred conditions of refluxing formic acid are employed. Upon completion of the dehydration reaction, the product, an olefinic benzimidazole of formula I, can be isolated by simply washing the reaction mixture with a base, for instance  
20 dilute aqueous sodium bicarbonate or the like, and removing the organic reaction solvent by evaporation. The product can be further purified if desired by normal methods, including chromatography and crystallization from solvents such as ethanol, ethyl acetate,  
25 acetone, and the like.

It should be noted that when  $R_7$  and  $R_8$  in the above general formula IG defining the olefinic benzimidazoles are different, the compounds exist as cis (or Z) and trans (or E) isomers. The dehydration  
30 reaction described above generally provides a mixture

of such isomers. For example, dehydration of a compound such as 1-isopropyl-2-amino-5-( $\alpha$ -hydroxy- $\alpha$ -cyanomethylbenzyl)benzimidazole affords a mixture of cis-1-isopropyl-2-amino-5-( $\alpha$ -cyanomethylenebenzyl)-benzimidazole, and the corresponding trans isomer. The cis and trans isomers of the benzimidazoles provided herein are represented by the general formulas:



wherein  $R_1$ ,  $R_2$ , and  $R_6$  are as described hereinabove, and  $R_7'$  is the same as  $R_7$  (or  $R_8$ ) but not hydrogen. Since both the cis and the trans olefinic benzimidazoles of formula I are potent antiviral agents, they can be utilized in the treatment of viral infections either alone or as a mixture.


Isolation of pure cis and pure trans olefinic benzimidazoles of formula I generally is accomplished, by part (Q) above, by chromatography or by crystallization or fractional crystallization from solvents such as methanol, ethanol, acetone, or the like. The trans isomers usually appear more active than the cis compounds, and therefore are preferred over the cis isomers.

X-5513

-30-

The benzimidazole carbinols which are the required starting materials in the above-described dehydration reaction are themselves antiviral agents. Some of the carbinols are prepared by reaction of a 5-  
 5 or 6-carbonyl substituted benzimidazole with a suitably substituted carbanion. For example, a carbanion of the formula  $R_7''CH_2^\ominus$  reacts with a ketobenzimidazole of the formula

10



15 wherein  $R_1$ ,  $R_2$ , and  $R_6$  are the same as described herein above and  $R_7''$  is  $-CN$ ,  $-CONH_2$ , or  $-CO_2(C_1-C_4 \text{ alkyl})$  to form the corresponding benzimidazole carbinol. The ketobenzimidazoles are available by the methods described previously. The requisite carbanions are  
 20 formed by reaction of an active methylene compound with a strong base such as methyl lithium, sodium hydride, n-butyl lithium, lithium diisopropylamide, potassium tert-butoxide, and the like. Active methylene compounds are those which have an electronegative functional group attached to a methyl or methylene group.  
 25 Typical active methylene compounds which readily form carbanions include compounds of the formulas  $CH_3CN$ ,  $CH_3CONH_2$ , and  $CH_3CO_2(C_1-C_4 \text{ alkyl})$ . Protected forms of the active methylene compounds can also be employed;  
 30 for instance, bis(trimethylsilyl)acetamide may be used

X-5513

-31-

in place of acetamide. Such compounds generally are reacted with about an equimolar quantity or an excess of strong base in an unreactive organic solvent such as diethyl ether, tetrahydrofuran, dimethylformamide, dioxane, diglyme, and the like. For example, an active methylene compound such as ethyl acetate can be reacted with a strong base such as *n*-butyl lithium in a solvent such as diethyl ether to form the corresponding carbanion, namely lithium ethoxycarbonylcarbanion. Such reactions typically are carried out at a temperature of about -78 to about -50°C., and are substantially complete within about one to about six hours.

Once the carbanion has formed, it typically is not isolated, but rather is reacted in situ with a ketobenzimidazole derivative. The carbanion generally is utilized in an excess of about 1 to about 10 molar compared to the ketobenzimidazole, and the reaction is routinely carried out at a temperature of about -70 to about 30°C. The product of the reaction is the aforementioned carbinol benzimidazole, and can be isolated by simply acidifying the reaction mixture, for example with hydrochloric acid, and then removing the reaction solvent, for instance by evaporation under reduced pressure. Further purification of the carbinol benzimidazole generally is not needed, but if desired can be accomplished by routine procedures such as chromatography, crystallization, and the like.


The ( $\alpha$ -hydroxy- $\alpha$ -C<sub>1</sub>-C<sub>7</sub> alkyl) derivatives are prepared by reacting the corresponding keto derivative with the appropriate Grignard reagent followed by hydrolysis in the usual manner.



X-5513

-32-

The compounds of formula I wherein  $R_3$  is  $Z=C(R_6)-$  and  $Z$  is  $=CHCl$  and  $=CHBr$  can be prepared, by part (N) above, by direct halogenation of a 5- or 6-( $\alpha$ -methylenemethyl)benzimidazole derivative. Such  
 5 reaction can be depicted by the following general scheme:



20 wherein  $R_1$ ,  $R_2$  and  $R_6$  are as defined above, one of  $R_9$  and  $R_{10}$  is hydrogen and the other of  $R_9$  and  $R_{10}$  is chloro or bromo.

The methylenemethyl benzimidazoles of formula IGc which are required as starting materials  
 25 for the halogenation reaction are prepared by the action of a methyl Grignard reagent on a ketobenzimidazole, followed by dehydration of the resulting carbinol, as discussed previously. The halogenating agents commonly utilized in the halogenation reaction  
 30 include N-chlorosuccinimide and N-bromosuccinimide.

The halogenation reaction generally is carried out by combining the benzimidazole with the halogenating agent in a suitable unreactive organic solvent such as benzene, tetrahydrofuran, chloroform, toluene, diethyl ether, or related solvents. The use of about an equimolar quantity of halogenating agent effects monohalogenation to give a compound wherein one of  $R_9$  and  $R_{10}$  is bromo or chloro and the other is hydrogen. The use of a two molar amount or larger excess of a halogenating agent effects dihalogenation and produces a compound wherein  $R_9$  and  $R_{10}$  both are halo, e.g. where  $R_9$  and  $R_{10}$  are independently chloro or bromo. The reaction generally is carried out at a temperature of about 20 to about 80°C., and normally is complete within about one to about seventy-two hours at such temperature. The product is isolated by simply cooling the reaction mixture and removing the reaction solvent, for instance by evaporation under reduced pressure. The compounds thus prepared can be further purified if desired by chromatography, crystallization, or the like.

It will be appreciated that advantageous chemical reactions can be performed at optional stages of product synthesis. The benzimidazole reactant can be chemically modified and then reacted with the appropriate  $R_1X$  to provide the desired product of formula I. Alternatively, a  $R_1$ -substituted benzimidazole intermediate can be prepared and then chemically modified to provide the final product. Suitable benzimidazole reactants are those having substituent groups which can

X-5513

-34-

be converted to the desired 5(6)-substituents either prior to or after reaction with the appropriate  $R_1X$ .

The pharmaceutically acceptable acid addition salts of formula I include salts derived from inorganic acids such as hydrochloric acid, nitric acid, phosphoric acid, sulfuric acid, hydrobromic acid, hydroiodic acid, phosphorous acid and the like, as well as salts derived from nontoxic organic acids such as aliphatic mono and dicarboxylic acids, phenyl-substituted alkanolic acids, hydroxy alkanolic and alkanedioic acids, aromatic acids, aliphatic and aromatic sulfonic acids, etc. Such pharmaceutically acceptable salts thus include sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, nitrate, phosphate, monohydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate, chloride, bromide, iodide, fluoride, acetate, propionate, decanoate, caprylate, acrylate, formate, isobutyrate, caprate, heptanoate, propiolate, oxalate, malonate, succinate, suberate, sebacate, fumarate, maleate, mandelate, butyne-1,4-dioate, hexyne-1,6-dioate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, hydroxybenzoate, methoxybenzoate, phthalate, terephthalate, benzenesulfonate, toluenesulfonate, chlorobenzenesulfonate, xylenesulfonate, phenylacetate, phenylpropionate, phenylbutyrate, citrate, lactate,  $\beta$ -hydroxybutyrate, glycollate, malate, tartrate, methanesulfonate, propanesulfonate, naphthalene-1-sulfonate, naphthalene-2-sulfonate, and the like salts. Salts from inorganic acids are preferred, especially the hydrochloride salt.

The benzimidazole compounds of formula I were tested as pure compounds and as isomer mixtures. Both isomers inhibit virus growth, the 6-isomer generally being more active than the 5-isomer against the Polio I virus usually used for ascertaining biological activity.

As already pointed out, an additional embodiment of this invention is a pharmaceutical formulation useful in the treatment and prophylactic control of viral infections in mammals, especially humans. The formulations comprise a benzimidazole of formula I in combination with a pharmaceutical diluent, excipient or carrier therefor. The formulation will contain about 0.5 to about 95% by weight of active ingredient. The compounds of formula I may be formulated for convenient oral administration by being mixed with solid diluents such as lactose, sorbitol, mannitol, starch, including potato starch and corn starch, amylopectin, cellulose derivatives, magnesium stearate, calcium stearate, polyethyleneglycol waxes, polyvinylpyrrolidone, and related diluents and excipients. Such formulations ideally are compressed into tablets for convenient oral administration. Alternatively, the formulations may be encapsulated in gelatin capsules or the like, or may be molded into a tablet suited to sublingual administration. The 2-amino benzimidazole compounds of formula IB are preferably administered by the oral route, while it is preferred that the 2-hydrogen compounds of formula I be administered by other than the oral route.

X-5513

-36-

The compounds of formula I may also be administered rectally, and formulations suited to such administration ideally are prepared in the form of suppositories, which contain a benzimidazole of formula I admixed with a suitable neutral fat base or  
5 with a vegetable oil or paraffin oil.

Liquid preparations for oral administration may be prepared in the form of syrups or suspensions. Such formulations will contain about 0.5 to about 20  
10 percent by weight of a compound of formula I, in combination with any of a number of suitable adjuvants such as sugar, ethanol, water, glycerol, propylene glycol and the like.

The benzimidazoles provided by formula I  
15 also may be administered parenterally to a mammal suffering from a viral infection or in need of prophylactic treatment. For such administration, solutions may be prepared by dissolving a compound of formula I, particularly as an acid addition salt, in a  
20 suitable solvent such as isotonic saline, aqueous glucose, or the like. The solutions will contain from about 0.5 to about 80 percent by weight of a benzimidazole of formula I, preferably about 1 to about 20 percent by weight.

25 The compounds of formula I may also be formulated as a nasal spray or inhaler. Such formulations will contain ideally about 0.5 to about 10 percent by weight of a benzimidazole. Nasal sprays will generally contain about 0.5 to about 5 percent by  
30 weight of active ingredient, and will contain carriers

X-5513

-37-

such as non-ionic polyoxyethylated oils, alcohols such as ethanol, flavor agents such as menthol, and propellants such as polyhalogenated methanes.

5 A further embodiment of this invention is a benzimidazole derivative of formula I, or a pharmaceutically acceptable salt thereof, for use as an antiviral agent. The method includes treating mammals, including humans, suffering from a viral infection or in need of prophylactic control of viral infections.

10 The method includes treatment of domesticated animals such as swine, cattle, horses, and the like. The method comprises administering to a mammal an antiviral amount of a benzimidazole of formula I. As hereinabove pointed out, the compounds can be suitably formulated

15 for convenient administration by any of several routes, including the oral and parenteral routes. While the particular dosage of active compound may vary depending upon the particular benzimidazole selected, the route of administration, the specific virus to be treated or

20 guarded against, the tolerance of the host, and various other parameters known to the medical community, the general rule is that a benzimidazole of formula I will be administered in an antiviral amount, which generally is a dose of about 0.1 to about 500 mg./kg.

25 of animal body weight. A typical dose of active compound will more preferably be about 0.5 to about 250 mg./kg., and ideally about 1 to about 100 mg./kg. Such dosage can be administered about once each day, or in the case of more severe viral infections, the dosage

30 can be administered from two to three times each day or

X-5513

-38-

more often as required. Such repeated dosing may be especially desirable when a compound is formulated as a nasal spray.

In an effort to more fully illustrate this invention, the following detailed preparations and examples are provided. The examples are illustrative only and are not intended to limit the scope of the invention. The term "m/e" used in characterizing the products refers to the mass-to-charge ratio of ions which appear in the mass spectra of the products. The values which correspond to molecular weights of the major peaks are designated " $M^+$ " with the first listed number being the parent peak. When salts were formed, their yields were approximately quantative to the yields of the free base.

Examples 1 and 2

1-Allyl-5-benzoylbenzimidazole and 1-allyl-6-benzoylbenzimidazole

To a solution of 8.8 g. of 5(6)-benzoylbenzimidazole in 150 ml. of dimethylformamide was added 5 ml. of allyl bromide. Two grams of a 50% sodium hydride suspension in oil were added and the reaction was stirred for about two hours at room temperature. The reaction mixture was poured into 300 ml. of ethyl acetate. The resulting suspension was washed three times with 300 ml. of a saturated sodium chloride solution and the organic layer was then evaporated to dryness, giving the title products as a mixture of the 5- and 6-isomers. Mass spectrum  $M^+$  = 262, 185, 157, 105 and 77.

Analysis:  $C_{17}H_{14}N_2O$ ;

Calc.: C, 77.84; H, 5.38; N, 10.68;

Found: C, 77.92; H, 5.22; N, 10.46.

5           The individual isomers were separated by chromatography over silica gel eluting with 70-80% ethyl acetate/20-30% hexane. In the above example, 1.7 g. of the pure 5-isomer, 1.4 g. of the pure 6-isomer, and an additional amount of unresolved product  
10 were recovered by chromatography.

#### Examples 3-10

          Following the procedure of Examples 1-2, the compounds of Table I were prepared using the appropriate benzimidazole and  $R_1X$  halide.  
15

          Some of the products were converted to the hydrochloride salt in the usual way. Those compounds which are the hydrochloride salt are marked with an asterisk (\*).

20           In the following tables, "W" refers to the substitution in the phenyl ring. Some of the compounds were not resolved into the pure isomers and are referred to as "5/6". Compounds which were resolved into the pure isomers are designated "5" or "6".

25

30



5

10


15

20

25

30

Table I



Example No.	R <sub>1</sub>	Isomer	W	M <sup>+</sup>		Yield (g.)
3	benzyl	5/6	H	312	235 105 91 77	3.00
4	phenyl	6	H	298	221 193 105 77 51	2.12
5	p-nitro-phenyl	5/6	H	343	266 220 164 105 77	10.00
6	isopropyl	5/6	H	264	187 145 117 105 77	3.46
7*	isopropyl	6	H	264	187 145 117 105 77	--
8*	isopropyl	5	2',4',6'-trimethyl	306	277 235 187 147 119 117	2.60
9*	isopropyl	6	2',4',6'-trimethyl	306	289 277 187 147 119 117	1.60
10	morpholin-ylmethyl	5/6	H	321	222 145 100 77	20.13

Example 11

## 1-(2-pyridyl)-6-benzoylbenzimidazole

To a solution of 4.44 g. (20 mmoles) of  
5 5(6)-benzoylbenzimidazole in 50 ml. of dimethylforma-  
mide was added 1.9 ml. (20 mmoles) of 2-chloropyridine.  
After adding 1 g. of sodium hydride (20 mmoles, 50% oil  
suspension), the reaction was heated to reflux over-  
night. The reaction was cooled and poured into ethyl  
10 acetate and the resulting suspension was washed three  
times with 300 ml. portions of a saturated sodium  
chloride solution. The organic solution was dried over  
magnesium sulfate and evaporated to dryness. The  
residue was chromatographed over silica gel eluting  
15 with 80% ethyl acetate/20% hexane, giving 1.01 g. of  
1-(2-pyridyl)-5-benzoylbenzimidazole and 0.54 g. of  
1-(2-pyridyl)-6-benzoylbenzimidazole.

1-(2-pyridyl)-5-benzoylbenzimidazole,  $M^+$  =  
299, 222, 194, 167, 105 and 77.

20 Analysis:  $C_{13}H_{13}N_3O$ ;

Calc.: C, 76.24; H, 4.38; N, 14.04;

Found: C, 76.26; H, 4.66; N, 14.34.

1-(2-pyridyl)-6-benzoylbenzimidazole,  $M^+$  =  
25 299, 222, 194, 167, 105 and 77.

Analysis:  $C_{13}H_{13}N_3O$ ;

Calc.: C, 76.24; H, 4.38; N, 14.04;

Found: C, 76.42; H, 4.28; N, 14.01.

Example 12

1-(Dimethylaminomethyl)-5(6)-benzoylbenzimidazole

- 5           A 40% aqueous solution of dimethylamine (11.3 ml., 100 mmoles) was added to a suspension of 22.3 g. (100 mmoles) of 5(6)-benzoylbenzimidazole in 300 ml. of methylene chloride, followed by the dropwise addition of 15 ml. of a 37% aqueous solution of formaldehyde.
- 10 After stirring at room temperature for three days, the solution was extracted first with water, and then with 1N sodium hydroxide. The organic phase was dried over magnesium sulfate and was then evaporated. The resulting residue was crystallized from ethyl acetate to
- 15 give 17.2 g. of the title products,  $M^+ = 279, 222, 145, 117, 105, \text{ and } 77$ .

Analysis:  $C_{17}H_{17}N_3O$ ;

Calc.: C, 73.10; H, 6.13; N, 15.04;

Found: C, 72.53; H, 6.11; N, 14.05.

20

General Preparation 1

The following typical procedures were used to regioselectively prepare 5- and 6-substituted-2-amino-benzimidazole compounds of Formula I.

- 25 A. Reaction of a 3-chloro-4-nitrobenzophenone with  $R_1NH_2$ .

1. Procedure when  $R_1NH_2$  is a volatile amine

- 30 Fifty grams of the 3-chloro-4-nitrobenzophenone, 100 ml. of the amine, and 300 ml. of methanol were heated to about 145°C. for 16 hours in a stainless

steel autoclave. The reaction mixture was worked up by removing the solvent by evaporation, adding 6N hydrochloric acid, and heating to reflux for about 20 minutes. Upon cooling, ethyl acetate was added and 5N sodium hydroxide was added to a pH of about 9. The organic layer was separated, dried over magnesium sulfate, and evaporated. The product was purified by chromatography over silica gel eluting with 10% ethyl acetate/90% hexane. The 3-amino-4-nitrobenzophenone thus isolated was used without further purification for the subsequent step (B).

2. Procedure when  $R_1NH_2$  is a non-volatile amine

About 15 g. of the chloronitrobenzophenone, 10 g. of anhydrous sodium carbonate, and one equivalent of the amine in 200 ml. of sulfolane were heated to 130-140°C. for 3 to 3.5 hours and worked up as described above.

3. Procedure when  $R_1NH_2$  is an aromatic amine

The conditions utilized were the same as for non-volatile amines, except that the reaction mixture was heated to 180-190°C. for about 16 hours.

B. Hydrogenation of 3-amino-4-nitrobenzophenones to 3,4-diaminobenzophenones.

About 72 g. of the 3-amino-4-nitrobenzophenone were hydrogenated overnight in 2.9 L. of tetrahydrofuran under 4.22 kg/cm.<sup>2</sup> at room temperature with about 15 g. of Raney nickel. The catalyst was removed

X-5513

-44-

by filtration and the solvent was removed in vacuo. The resulting diaminobenzophenone was used without purification for the subsequent steps.

5 C. Preparation of 2-aminobenzimidazoles.

Equal molar amounts of the 3,4-diaminobenzophenone and cyanogen bromide were stirred overnight in 90% methanol/10% water. The methanol was then removed in vacuo and ethyl acetate was added. The solution was  
10 washed once with a saturated solution of sodium bicarbonate. The solution was then dried and evaporated to a solid residue. Column chromatography over silica gel eluting with a 0-5% step gradient of methanol in ethyl acetate gave the desired product in about a 60% yield.

15 Examples 13-19


Following the procedures of General Preparation 1, the compounds of Table II were prepared.

20

25

30

Table II



Example No.	R <sub>1</sub>	Isomer	W	M <sup>+</sup>	yield (g.)									
13	cyclohexyl	6	H	319 237 208 160 132 105 77	58	43							14.0	
14	cyclohexyl	6	4'-OCH <sub>3</sub>	349 334 267 160 135									1.5	
15	cyclohexyl	6	4'-F	337 255 160 123									1.0	
16	isopropyl	6	H	279 202 160 105 77									4.5	
17*	isopropyl	6	H	279 202 160 132 105 77									--	
18	phenyl	6	H	313 236 208 105 77									4.0	
19	allyl	5	H	277 200 105 77									2.0	

### General Preparation 2

Using the substituted diaminobenzophenones of General Preparation 1 (A and B), the 2-unsubstituted benzimidazoles of Examples 1-11 could be prepared by the reaction with formic acid giving the pure 5- and 6-isomers.

In a typical preparation, 50 g. of the diamine were mixed with 50 ml. of 98% formic acid and 100 ml. of 6N hydrochloric acid. The mixture was refluxed for three hours, cooled, neutralized to a pH of about 7 with 2N sodium hydroxide, and extracted with ethyl acetate. The organic layer was dried over magnesium sulfate and evaporated to dryness. The residue was purified by column chromatography over silica gel, eluting with 70% ethyl acetate/30% hexane. The usual yield of the pure isomers was about 50%.

### Example 20

1-isopropyl-2-(1-hydroxyethyl)-6-benzoyl-benzimidazole

Reacting 3-isopropylamino-4-aminobenzophenone, prepared by General Preparation 1 (A and B), with lactic acid according to the procedure of General Preparation 2 gave 2 g. the title product,  $M^+ = 308$ , 293, 265, 251, 231, 189, 171, 143, 117, 105, 77 and 43.

Analysis:  $C_{19}H_{20}N_2O_2$ ;

Calc.: C, 74.00; H, 6.54; N, 9.08;

Found: C, 73.90; H, 6.40; N, 8.87.

X-5513

-47-

Examples 21 and 22

1-(1-cyclohexenyl)-2-hydroxy-5-benzoylbenzimidazole and 1-(1-cyclohexenyl)-2-hydroxy-6-benzoylbenzimidazole

5 Ten grams of 3,4-diaminobenzophenone and eight milliliters of ethyl 2-cyclohexanone carboxylate were refluxed overnight in xylene. The resulting precipitate was filtered hot to give 2.7 g. of 1-(1-cyclohexenyl)-2-hydroxy-5-benzoylbenzimidazole,  $M^+ =$   
10 318, 241, 238, 213, 161, 133, 105 and 77.

The filtrate from above was cooled and concentrated in vacuo resulting in a precipitate which was recovered by filtration, affording 1.5 g. of pure  
15 1-(1-cyclohexenyl)-2-hydroxy-6-benzoylbenzimidazole,  $M^+ =$  318, 241, 238, 213, 161, 105, 91 and 77.

Analysis:  $C_{20}H_{18}N_2O_2$ ;

Calc.: C, 75.45; H, 5.70; N, 8.80;

Found: C, 75.27; H, 5.68; N, 8.56.

20 Example 23

2-methylmercapto-1-benzyl-5(6)-benzoylbenzimidazole

A. Preparation of 2-thio-5(6)-benzoylbenzimidazole

25 Twenty grams (80.6 mmoles) of 3,4-diaminobenzophenone were dissolved in 300 ml. of methanol and 45 ml. of water. Potassium ethyl xanthate (12.9 g.,

30



X-5513

-48-

80.6 mmoles) was added and the reaction mixture was heated to reflux for three hours. Twelve grams of decolorizing charcoal were added and the reaction was refluxed an additional ten minutes. The reaction mixture was cooled and filtered and the solvent of the filtrate was removed by evaporation. Ethyl acetate (200 ml.) was added. The organic solution was washed twice with a saturated solution of sodium chloride and once with 1N hydrochloric acid. The organic phase was dried over magnesium sulfate and evaporated to dryness. Crystallization of the residue from 30% ether/70% ethyl acetate gave 14.5 g. of 2-thio-5(6)-benzoylbenzimidazole.

B. Preparation of 2-methylmercapto-5(6)-benzoylbenzimidazole

Five grams of 2-thio-5(6)-benzoylbenzimidazole and five grams of sodium bicarbonate were added to 40 ml. of dimethylformamide, followed by 2.4 ml. of methyl iodide. After 15 minutes, the reaction mixture was added to 150 ml. of ethyl acetate.

The ethyl acetate solution was washed three times with a saturated solution of sodium chloride. The organic phase was dried over magnesium sulfate and evaporated. The resulting oil was washed with hexane to remove residual dimethylformamide, and the residue was crystallized from cold ether to give 1.7 g. of 2-methylmercapto-5(6)-benzoylbenzimidazole,  $M^+ = 268$ .

30

X-5513

-49-

Analysis:  $C_{15}H_{12}N_2OS$ ;

Calc.: C, 67.14; H, 4.51; N, 10.44;  
S, 11.95;

Found: C, 67.12; H, 4.89; N, 10.14;  
S, 11.97.

5

C. Preparation of 2-methylmercapto-1-benzyl-5(6)-  
benzoylbenzimidazole

2-Methylmercapto-5(6)-benzoylbenzimidazole  
10 (10 g.) was dissolved in 50 ml. of dimethylformamide,  
followed by 4.8 g. of sodium hydride and 4.43 ml. of  
bromotoluene. The reaction mixture was stirred at  
room temperature for four hours, then washed and  
poured into water. After 30 minutes, the reaction  
15 mixture was poured into ethyl acetate.

The ethyl acetate solution was washed three  
times with a saturated solution of sodium chloride.  
The organic phase was dried over magnesium sulfate  
and evaporated. To the residue was added ethyl  
20 ether and the mixture was chilled to about 0°C.  
The product crystallized and was purified by chroma-  
tography using 50% ethyl acetate/hexane to give 5 g.  
of 2-methylmercapto-1-benzyl-5(6)-benzoylbenzimidazole,  
 $M^+ = 358, 267, 105, 91$  and 77.

25

30

### General Preparation 3

The following general preparation was used to convert ketones ( $R_3$  is  $O=C(R_6)-$ ) to the corresponding oximes.

5           One gram of the ketone is dissolved in 15 ml. of methanol and 5 ml. of pyridine. One gram of hydroxylamine hydrochloride is added and the reaction is refluxed for three hours. The reaction is added to a mixture of 200 ml. of ethyl acetate and 200 ml. of a  
10           saturated solution of sodium chloride. The pH is adjusted to about 7 with 1N sodium hydroxide, and the organic layer is separated. The organic layer is dried over magnesium sulfate and evaporated. The desired  
15           oxime crystallizes on concentration of the solvent or the residue can be crystallized from small amounts of ethyl acetate. The reaction usually gives about a 50/50 mixture of the syn and anti isomers.

### Examples 24-66

20           Following the procedure of General Preparation 3, the compounds of Examples 24-66 in Table III were prepared. Those examples marked with an asterisk (\*) were converted to the hydrochloride salt from the free base in the following manner:

25           For oxime derivatives which were soluble in dilute hydrochloric acid, the oxime was dissolved in a minimum volume of 1N hydrochloric acid and the solution brought to dryness in vacuo. The residue was crystallized from a small volume of acetone to give the  
30           desired product.

X-5513

-51-

For oxime derivatives that are not soluble in 1N hydrochloric acid, several equivalents of acetyl chloride was added to dry methanol, and the oxime was dissolved in the methanolic hydrogen chloride solution.

- 5 Evaporation of the solvent gave the desired product which, if not already crystalline, could be crystallized from small volumes of acetone.

Some of the pure 5- and 6-isomers were prepared from the pure isomers of the corresponding ketone while others were resolved by crystallization and/or chromatography after a mixture of the oxime isomers was obtained by reacting hydroxylamine with a mixture of the 5- and 6-substituted ketones. All of the oxime derivatives were analyzed and tested as the mixture of

15 syn and anti isomers.

20

25

30

X-5513

-52-

5

10


15

20

25


30

Table III




Example No.	R <sub>1</sub>	R <sub>2</sub>	Isomer	W	M <sup>+</sup>	Yield (g.)
24	isopropyl	H	5/6	H	279 262 220 160 145 77	14.5
25*	isopropyl	H	6	H	279 264 262 220 160 145 77	--
26	isopropyl	H	5	H	279 262 220 160 145 90 77	0.4
27*	isopropyl	H	5	H	279 262 220 187 145 117 105 77	--
28	cyclohexyl	H	5/6	H	319 302 220 145 105 77	0.09
29*	cyclohexyl	H	6	H	319 302 220 200 145 118 105 77	--
30	benzyl	H	6	H	327 310 219 208 91 77	0.96
31	benzyl	H	5	H	327 310 219 208 105 91 77	0.49
32	phenyl	H	6	H	313 296 194 166 91 77 51	0.60
33*	phenyl	H	6	H	313 296 194 166 77	0.30
34	phenyl	H	6	4'-chloro	347 330 296 194 166 139 77	0.33

Table III cont'd.




Example No.	R <sub>1</sub>	R <sub>2</sub>	Isomer	W	M <sup>+</sup>	Yield (g.)
35	p-nitro-phenyl	H	5/6	H	358 341 295 239 115 77	1.4
36**	p-amino-phenyl	H	5/6	H	328 311 251 209 179 77 65	0.6
37	2-pyridyl	H	6	H	314 297 195 164 106 78 77	0.11
38	2-pyridyl	H	5	H	314 297 195 167 105 78 77	0.11
39	1-adamantyl	H	6	H	371 355 135 107 93 79	0.9
40	cyclopropyl	H	6	H	277 260 157 131 77 41	0.9
41	n-hexyl	H	6	H	321 304 220 202 131 77	1.5
42	n-hexyl	H	5	H	321 304 220 202 131 105 77	0.71
43	allyl	H	5	H	277 260 219 205 156 103 77 41	0.6
44	allyl	H	6	H	277 260 219 205 156 103 77 41	1.1
45	2-thiazolyl	H	6	H	320 303 217 201 105 77	0.3
46	morpholin-ylmethyl	H	5/6	H	336 237 220 100 77	2.2
47	CH <sub>2</sub> CH(OH)CH <sub>3</sub>	H	6	H	295 278 250 234 176 130 103 77 45	1.5

Table III cont'd.



Example No.	R <sub>1</sub>	R <sub>2</sub>	Iso-mer	W	M <sup>+</sup>	Yield (g.)
48	t-butyl	H	6	H	293 277 237 220 195 118 93	0.5
49	cyclohexyl	NH <sub>2</sub>	6	H	334 318 252 235 215 133 105 79	1.0
50	cyclohexyl	NH <sub>2</sub>	6	4'-OCH <sub>3</sub>	364 348 265 215 133 105 77 55	0.75
51	cyclohexyl	NH <sub>2</sub>	6	3'-CH <sub>3</sub>	348 331 249 215 133 105 79	0.5
52	cyclohexyl	NH <sub>2</sub>	6	2'-CH <sub>3</sub>	348 331 249 133 105 91	1.0
53	cyclohexyl	NH <sub>2</sub>	6	4'-F	352 336 253 133 105 55 41	0.7
54	2-pyridyl	NH <sub>2</sub>	6	H	(D) 252 235 133 105 77	0.26
55	1-adamantyl	NH <sub>2</sub>	6	H	386 370 234 135 93 79	0.22
56*	isopropyl	NH <sub>2</sub>	6	H	294 277 264 235 133 105 77	--
57	CH <sub>2</sub> CH(OH)CH <sub>3</sub>	NH <sub>2</sub>	6	H	310 293 249 191 145 77 45	0.75
58	isopropyl	NH <sub>2</sub>	6	H	294 277 264 235 175 133 91 77 51 43	3.0
59	phenyl	NH <sub>2</sub>	6	H	328 311 233 209 167 165 77 63 51	0.4
60	2-pyridyl	NH <sub>2</sub>	5	H	329 313 252 235 220 133 105 77	0.08
61	allyl	NH <sub>2</sub>	5	H	292 275 234 220 173 132 104 77	0.36
62	1-cyclohexenyl	OH	5	H	333 317 316 288 253 236 214 134 104 79 52	0.53

Table III cont'd.



Example No.	R <sub>1</sub>	R <sub>2</sub>	ISO-mer	W	M <sup>+</sup>	Yield (g.)
63	1-cyclohexenyl	OH	6	H	333 317 288 253 236 214 134 104 79	0.95
64	isopropyl	CH(OH)-CH <sub>3</sub>	6	H	323 306 266 144 118 77	0.80
65	benzyl	SCH <sub>3</sub>	5	H	373 356 282 162 91 77	0.46
66	benzyl	SCH <sub>3</sub>	6	H	373 356 282 162 91 77	0.62

\* - hydrochloride salt

\*\* - prepared from the p-nitrophenyl derivative, Ex. 35, by reduction.

D - m/e = 252 (M<sup>+</sup> -77)



X-5513

-56-

Example 67

1-(dimethylaminomethyl)-5(6)-(α-hydroxyimino-benzyl)benzimidazole

5 To a suspension of 7.11 g. (30 mmoles) of  
5(6)-(α-hydroxyiminobenzyl)benzimidazole, in 90 ml. of  
methylene chloride was added 3.4 ml. of a 40% aqueous  
solution of dimethylamine, followed by 4.5 ml. of a 37%  
aqueous solution of formaldehyde. The reaction was  
10 stirred for three days at room temperature and then  
washed with 100 ml. of 1N sodium hydroxide. The or-  
ganic layer was separated, dried over magnesium sulfate,  
and removed by evaporation to give a gum. Crystalliza-  
tion of the gum from 20 ml. of 50% aqueous methanol  
gave 1.95 g. of a mixture of the title isomers,  $M^+ =$   
15 237 ( $M^+ - 57$ ), 220, 205, 134, 118, 105, 90 and 77.

Example 68

1-isopropyl-2-isopropylamino-5(6)-(α-hydroxyiminobenzyl)benzimidazole

20 When 2-amino-5(6)-benzoylbenzimidazole was  
treated with two equivalents of sodium hydride and an  
excess of isopropyl bromide according to the procedure  
of Examples 1-2, the dialkylated 1-isopropyl-2-iso-  
propylamino-5(6)-benzoylbenzimidazole products were  
25 obtained. Treatment of this intermediate with hydroxyl-  
amine hydrochloride according to the procedure of  
Preparation 3 gave the title products, yield 240 mg.,  
as an isomeric mixture,  $M^+ = 336, 252, 235, 220, 159,$   
133, 105 and 77.

30

X-5513

-57-

Analysis:  $C_{20}H_{24}N_4O$ ;

Calc.: C, 71.40; H, 7.19; N, 16.65;

Found: C, 71.63; H, 7.24; N, 16.47.

Example 69

5

1-isopropyl-2-amino-6-(1-phenylethenyl)-  
benzimidazole

Three grams (10.7 mmoles) of 1-isopropyl-2-amino-6-benzoylbenzimidazole were dissolved in 25 ml. of tetrahydrofuran, after which was added 27 ml. of a 2M solution of methyl magnesium bromide in ethyl ether. After stirring overnight, ethyl acetate was added, and the solution was washed three times with a saturated sodium chloride solution. The organic solution was dried over magnesium sulfate, filtered, and evaporated under reduced pressure. One hundred milliliters of 98% formic acid were added to the residue. The solution was refluxed for 2 hours. The formic acid was evaporated under reduced pressure. Ethyl acetate was added, and the resulting solution was washed with a saturated sodium bicarbonate solution. After drying over magnesium sulfate, the solution was filtered and concentrated. Upon the addition of a small volume of ether, 2.0 g. of the title product solidified out of solution which was recovered by filtration,  $M^+ = 277, 235, 193, 165$  and 77.

30

X-5513

-58-

Example 70

1-isopropyl-2-amino-6-(1-phenyl-1-propenyl)-  
benzimidazole

5        Following the procedure of Example 69, 1-isopropyl-2-amino-6-benzoylbenzimidazole and ethyl magnesium bromide were reacted to give the title product, yield 600 mg., as both the cis and trans alkylene isomers,  $M^+ = 291, 279, 264, 248, 220, 202, 160$  and 43.

Example 71

10

1-isopropyl-2-amino-6-(1-phenyl-2-bromoethenyl)benzimidazole

15        Three hundred milligrams (1.08 mmoles) of 1-isopropyl-2-amino-6-(1-phenylethenyl)benzimidazole and 192 mg. (1.08 mmoles) of N-bromosuccinimide were refluxed overnight in 20 ml. of dry tetrahydrofuran. After cooling, ethyl acetate was added and the solution was washed with a saturated solution of sodium bicarbonate. The organic layer was dried over magnesium sulfate, filtered, and evaporated in vacuo. The residue was chromatographed over silica gel, first eluting with ethyl acetate to remove impurities, and then with 10% methanol/90% ethyl acetate. The title product was crystallized from ether giving 200 mg. of the cis/trans mixture,  $M^+ = 357, 313, 276, 234, 190, 165, 102, 77$  and 43.

20

25

30

Analysis:  $C_{18}H_{18}BrN_3$ ;

Calc.: C, 60.68; H, 5.09; N, 11.79; Br,  
22.43;

5 Found: C, 60.58; H, 5.24; N, 11.95; Br,  
22.13.

Example 72

1-isopropyl-2-amino-6-(1-phenyl-2-cyano-  
ethenyl)benzimidazole

10 Forty millimoles (2.1 ml.) of dry aceto-  
nitrile were added to 30 ml. of tetrahydrofuran. A  
nitrogen blanket was applied and the temperature of the  
solution lowered to about  $-78^{\circ}\text{C}$ . by means of an exter-  
nal acetone/dry ice bath. Twenty-five milliliters of a  
15 1.6M solution of n-butyl lithium were added. After  
stirring at  $-78^{\circ}\text{C}$ . for 30 minutes, a solution of 2.8 g.  
(10 mmoles) of 1-isopropyl-2-amino-6-benzoylbenzimid-  
azole in 30 ml. of tetrahydrofuran was added. The  
reaction solution was allowed to warm to about  $-20^{\circ}\text{C}$ .  
20 and was then stirred for 5 hours at  $-20$  to  $-5^{\circ}\text{C}$ . Water  
and ethyl acetate were then added and the layers were  
separated. The organic layer was dried over magnesium  
sulfate, filtered, and evaporated in vacuo. The resi-  
due was dissolved in 100 ml. of 98% formic acid. After  
25 stirring on a hot water bath for 2.5 hours, the solu-  
tion was evaporated under reduced pressure. The resi-  
due was dissolved in ethyl acetate and washed with a  
saturated solution of sodium bicarbonate. The organic  
solution was dried over magnesium sulfate, filtered,  
30 and evaporated. The residue was chromatographed over  
silica gel, eluting first with ethyl acetate to remove

X-5513

-60-

non-polar impurities, then with 10% methanol/90% ethyl acetate to elute the title product. The product was further purified by reverse phase chromatography, eluting with 60% aqueous methanol, followed by crystallization from methyl ethyl ketone, resulting in  
5 350 mg. of the title product,  $M^+ = 302, 270, 260, 236, 202, 160, 132, 105, 77$  and 43.

Example 73

10 1-phenyl-2-amino-6-(1-phenyl-2-cyanoethenyl)-benzimidazole

Following the procedure of Example 72, 3.1 g. of 1-phenyl-2-amino-6-benzoylbenzimidazole was transformed into 300 mg. of the title product,  $M^+ = 336,$   
15 259, 190, 168 and 77.

Analysis:  $C_{22}H_{16}N_4$ ;

Calc.: C, 78.55; H, 4.79; N, 16.66;

Found: C, 78.51; H, 4.52; N, 16.85.

Example 74

20 anti-3-(1-isopropyl-2-aminobenzimidazol-6-yl)-3-phenyl-2-propenamide hydrochloride

A solution of 8.37 g. of 1-isopropyl-2-amino-6-benzoylbenzimidazole in tetrahydrofuran was added to  
25 a solution of 95 ml. of a 1.6M solution of n-butyl lithium and 30.45 g. of bis(trimethylsilyl)acetamide in tetrahydrofuran which was previously cooled to about -70°C. The reaction was stirred for about two hours and the temperature was allowed to warm to about -10°C.

30

X-5513

-61-

The reaction was poured into an ice/ammonium chloride solution. The organic layer was separated, washed with water, and dried, giving both the syn- and anti-isomers of the title compound. Yield 50 mg. The residue was dissolved in a small volume of methyl ethyl ketone. After standing at room temperature overnight, the resulting crystals were recovered by filtration and identified as syn-3-(1-isopropyl-2-aminobenzimidazol-6-yl)-3-phenyl-2-propenamide,  $M^+ = 320, 303, 277, 234, 190$  and 105.

Analysis:  $C_{19}H_{20}N_4O$ ;

Calc.: C, 71.24; H, 6.47; N, 17.27;  
O, 5.19;

Found: C, 71.23; H, 6.29; N, 17.49;  
O, 4.99.

The mother liquor from the above product was evaporated, and the residue was dissolved in pyridine. Excess thionyl chloride was added and the solution was stirred at room temperature overnight. The reaction mixture was evaporated to dryness in vacuo. Water and ethyl acetate were added to the residue. The layers were separated and the water layer was adjusted to a pH of about 8. The water layer was extracted with ethyl acetate. The ethyl acetate was dried and evaporated to dryness to give the title anti-3-(1-isopropyl-2-aminobenzimidazol-6-yl)-3-phenyl-2-propenamide hydrochloride.

Analysis:  $C_{19}H_{20}N_4O \cdot HCl$ ;

Calc.: C, 63.19; H, 6.03; N, 15.04;  
O, 6.30; Cl, 9.74;

Found: C, 63.95; H, 5.93; N, 15.70;  
O, 4.48; Cl, 9.93.

X-5513

-62-

The following formulation examples may employ as active ingredients any of the pharmaceutical compounds of formula I.

Example 75

5

## Preparation of Tablets

	<u>Per Tablet</u>
1-cyclohexyl-2-amino-6-( $\alpha$ -hydroxyiminobenzyl)benzimidazole	250 mg.
Lactose	200 mg.
10 Corn starch	300 mg.
Corn starch paste	50 mg.
Calcium stearate	5 mg.
Dicalcium phosphate	45 mg.

15 The benzimidazole, corn starch, lactose and dicalcium phosphate are uniformly blended. The corn starch paste is prepared as a 10 percent aqueous paste and is blended into the mixture to uniformity. The mixture is blended with the calcium stearate and then compressed in tablets each weighing 850 mg.

20

Example 76

## Preparation for Suppositories

	<u>Per suppository</u>
25 1-isopropyl-5-acetylbenzimidazole	500 mg.
Theobroma oil	1500 mg.

The above ingredients are blended to uniformity at a temperature of about 60°C., poured into a suppository mold of nominal 2 g. capacity, and allowed  
30 to cool.

X-5513

-63-

Example 77

## Preparation for Oral Suspension

	<u>Per 100 ml.</u>
5 1-Ethyl-2-acetamido-6-(1-phenyl- 2-bromoethenyl)benzimidazole	500 mg.
Sorbitol solution (70% N.F.)	40 ml.
Sodium benzoate	150 mg.
Lactose	10 mg.
Cherry flavor	50 mg.
10 Water	q.s. to 100 ml.

The above ingredients are combined such that each ml. of syrup contains 5 mg. of active ingredient.

Example 78

## 15 Intranasal Formulation

	<u>Percent by weight</u>
20 1-(4-methoxyphenyl)-2-methyl- mercapto-6-[( $\alpha$ -ethenyl)-cyclo- hexylmethyl]benzimidazole	1.0
Antarox (non-ionic polyoxyethylated fixed oil, GAF Corp.)	38.5
Ethanol	10.0
Freon 11 (trichloromonofluoro- methane)	25.0
25 Freon 12 (dichlorodifluoromethane)	25.0
Menthol	0.5

The benzimidazole is added to the Antarox at about 70-80°C. and the mixture is stirred until a solution is formed. The solution is cooled and diluted  
30 with a mixture of the menthol in the ethanol. The



X-5513

-64-

resulting solution is placed in an aerosol container and chilled to 0°C., the Freon propellants are added, and the aerosol container is sealed with a valve.

The compounds of formula I were tested by the  
5 following method.

African green monkey kidney cells (BSC-1) or Hela cells (5-3) were grown in 25 cc. Falcon flasks at 37°C. in medium 199 with 5 percent inactivated fetal bovine serum (FBS), penicillin (150 units per ml.) and  
10 streptomycin (150 mcg./ml.). When confluent monolayers were formed, the supernatant growth medium was removed and 0.3 ml. of an appropriate dilution of virus (echo, Mengo, Cocksackie, polio or rhinovirus) was added to each flask. After absorption for one hour at room  
15 temperature, the virus infected cell sheet was overlaid with a medium comprising one part of 1 percent Ionagar No. 2 and one part double strength medium 199 with FBS, penicillin, and streptomycin which contains test compound at concentrations of about 100, 50, 25, 12, 6, 3,  
20 1.5, 0.75, and 0, and/or 12.5, 6.25, 3.12, 1.56, 0.78, 0.39, 0.19, 0.09, 0.04, and 0.02 micrograms per milliliter (mcg./ml.). The flask containing no test compound served as the control for the test. The stock solutions of benzimidazole compounds were made up in  
25 dimethylsulfoxide solution at a concentration of  $10^4$  mcg./ml. The flasks were incubated for 72 hours at 37°C. for polio, Cocksackie, echo, and Mengo virus and 120 hours at 32°C. for rhinovirus. Plaques were seen in those areas where the virus infected and reproduced  
30 in the cells. A solution of 10 percent formalin and 2 percent sodium acetate was added to each flask to

inactivate the virus and fix the cell sheet to the surface of the flask. The virus plaques, irrespective of size, were counted after staining the surrounding cell areas with crystal violet. The plaque count was compared to the control count at each test concentration. The activity of the test compound was expressed as percentage plaque reduction, or percent inhibition. Alternatively, the test concentration which inhibits plaque formation by 50 percent can be used as a measure of activity. The 50 percent inhibition is indicated by the symbol  $I_{50}$ .

Test results are expressed in terms of Polio virus type I inhibition because the virus is easy to grow and consistent test results are obtained. However, the activity of the preferred compounds was confirmed against other virus cultures such as Coxsackie (A9, A21, B5), echovirus (strains 1-4), Mengo, rhinovirus (25 strains) and Polio (type I, II, III). Test results for various benzimidazole compounds are summarized in Table IV below where column 1 gives the Example number from the previous chemical examples, column 2 gives the 5(6)-position of the corresponding benzimidazole product, and column 3 indicates the test compound concentration in micrograms per milliliter (mcg./ml.) which inhibits Polio I plaque formation by 50 percent ( $I_{50}$ ). In each case, 1-isopropylsulfonyl-2-amino-6-(syn- $\alpha$ -hydroxyiminobenzyl)benzimidazole was tested as a standard reference and gave an  $I_{50}$  in the range of 0.2-0.8 mcg./ml.

X-5513

-66-

Table IV

Polio I Plaque Reduction of 1-Substituted-  
5(6)-Substituted-Benzimidazoles

	<u>Example No.</u>	<u>Isomer</u>	<u>I<sub>50</sub> (mcg./ml.)**</u>
5	2	6	0.78
	6	5/6	6.0
	8	5	6.25
	9	6	6.25
	10	5/6	25
10	11	6	12.5
	12	5/6	12.5
	18	6	0.78
	21	5	>100
	22	6	6
15	24	5/6	0.19
	25*	6	0.39
	26	5	25
	27*	5	25
	28	5/6	0.19
20	29*	6	0.78
	30	6	0.39
	31	5	25
	32	6	0.09
	33*	6	0.09
25	34	6	0.19
	35	5/6	0.75
	36	5/6	0.09
	37	6	0.75
	38	5	>100
30	39	6	25
	40	6	0.39

X-5513

-67-

Table IV cont'd.

Polio I Plaque Reduction of 1-Substituted- 5(6)-Substituted-Benzimidazoles			
	Example No.	Isomer	I <sub>50</sub> (mcg./ml.)**
5	41	6	0.78
	42	5	100
	44	6	0.78
	45	6	0.78
	46	5/6	6
10	47	6	6.25
	48	6	0.19
	49	6	0.09
	50	6	0.09
	51	6	3.12
15	52	6	0.78
	53	6	1.5
	54	6	6
	55	6	0.75
	57	6	3.12
20	58	6	0.09
	59	6	0.09
	60	5	6
	62	5	3
	63	6	3
25	64	6	1.5
	65	5	50
	66	6	25
	67	5/6	6
	68	5/6	3
30	69	6	1.56

X-5513

-68-

Table IV cont'd.

Polio I Plaque Reduction of 1-Substituted-  
5(6)-Substituted-Benzimidazoles

	<u>Example No.</u>	<u>Isomer</u>	<u>I<sub>50</sub> (mcg./ml.)**</u>
5	70	6	0.78
	71	6	0.09
	72	6	0.04
	74*	6	0.39

10 \*-hydrochloride salt

\*\*-Drug concentration in micrograms per milliliter

15


20

25

30

CLAIMS

1. A benzimidazole compound of the formula



wherein:

- 10  $R_1$  is  $C_1-C_8$  alkyl,  $C_2-C_8$  alkenyl,  $C_3-C_7$  cycloalkyl,  $C_5-C_7$  cycloalken-1-yl, 2-pyridyl, 2-thiazolyl, adamantyl, hydroxy-substituted  $C_1-C_8$  alkyl, unsubstituted or substituted phenyl, unsubstituted or substituted benzyl, or  $R_4R_5NCH_2-$ ,  
 15 where  $R_4$  and  $R_5$  are independently  $C_1-C_3$  alkyl or  $R_4$  and  $R_5$ , when taken together with the nitrogen atom to which they are attached, are pyrrolidino, piperidino, or morpholino;  
 $R_2$  is hydrogen, amino,  $C_1-C_4$  alkylamino, methylmercapto, hydroxy,  $C_1-C_4$  acylamino, or 1-hydroxyethyl;  
 20  $R_3$  is  $C_2-C_8$  alkanoyloxy, unsubstituted or substituted phenylacetoxo, unsubstituted or substituted benzoyloxy, or  $R_6C-\underset{Z}{\overset{6''}{|}}$ ;  
 25  $Z$  is oxygen, hydroxyimino,  $C_1-C_4$  alkoxyimino,  $C_1-C_4$  acyloxyimino, hydrazono,  $C_1-C_7$  alkylidene,  $=CHBr$ ,  $=CHCl$ ,  $=CBr_2$ ,  $=CCl_2$ ,  $=CBrCl$ ,  $=CHCN$ ,  $=CHCONH_2$ ,  
 30 or  $=HCO_2(C_1-C_4 \text{ alkyl})$ ;

X-5513-(EPO)

-70-

$R_6$  is  $C_1$ - $C_7$  alkyl,  $C_3$ - $C_7$  cycloalkyl, ( $C_3$ - $C_7$  cycloalkyl)methyl, 2-( $C_3$ - $C_7$  cycloalkyl)ethyl, unsubstituted or substituted benzyl, unsubstituted or substituted phenyl; and

5  $R_3$  is at the 5 or 6 position, subject to the limitation that when  $R_2$  is hydroxy,  $R_1$  may only be  $C_5$ - $C_7$  cycloalken-1-yl; and the pharmaceutically acceptable salts thereof.

2. A compound of formula I of claim 1,  
10 wherein:  
 $R_1$  is  $C_1$ - $C_8$  alkyl,  $C_2$ - $C_8$  alkenyl, phenyl, substituted phenyl, or  $C_3$ - $C_7$  cycloalkyl;  
 $R_2$  is hydrogen or amino; and  
 $R_3$  is  $R_6\overset{\underset{Z}{\parallel}}{C}-$  wherein  $R_6$  is phenyl or substituted  
15 phenyl.

3. A compound of formula I of claim 1,  
wherein:  
 $R_1$  is isopropyl, cyclohexyl or phenyl;  
20  $R_2$  is hydrogen or amino; and  
 $R_3$  is  $R_6\overset{\underset{Z}{\parallel}}{C}-$  wherein  $R_6$  is phenyl and  $Z$  is oxygen,  
hydroxyimino, =CHBr, =CHCN, =CHCH<sub>3</sub>, or =CHCONH<sub>2</sub>.

4. A compound of formula I of claim 1, 2  
25 or 3, wherein  $R_3$  is at the 6 position.

5. Any one of the following compounds or its pharmaceutically acceptable salt:

30

X-5513-(EPO)

-71-

1-isopropyl-2-amino-6-(1-phenyl-1-propenyl)-  
benzimidazole,

1-isopropyl-2-amino-6-(1-phenyl-2-cyanoethenyl)-  
benzimidazole,

5 1-phenyl-2-amino-6-(1-phenyl-2-cyanoethenyl)-  
benzimidazole,

1-isopropyl-2-amino-6-(1-phenyl-2-bromoethenyl)-  
benzimidazole,

10 3-(1-isopropyl-2-amino-benzimidazol-6-yl)-  
3-phenyl-2-propenamide,

1-isopropyl-2-amino-6-( $\alpha$ -hydroxyiminobenzyl)-  
benzimidazole,

1-phenyl-2-amino-6-( $\alpha$ -hydroxyiminobenzyl)-  
benzimidazole,

15 1-cyclohexyl-2-amino-6-( $\alpha$ -hydroxyiminobenzyl)-  
benzimidazole,

1-cyclohexyl-2-amino-6-( $\alpha$ -hydroxyimino-4'-  
methoxybenzyl)benzimidazole,

20 1-(t-butyl)-6-( $\alpha$ -hydroxyiminobenzyl)benz-  
imidazole.

6. A benzimidazole derivative of formula I,  
or a pharmaceutically acceptable salt thereof, as  
claimed in any one of claims 1 to 5 for use as an  
antiviral agent.

25 7. A pharmaceutical formulation comprising  
as active ingredient a benzimidazole derivative of  
formula I, or a pharmaceutically acceptable salt  
thereof, as claimed in any one of claims 1 to 5 with  
one or more pharmaceutically acceptable carriers.

30

BAD ORIGINAL




X-5513-(EPO)

-72-

8. A pharmaceutical formulation of claim 7 wherein the active ingredient is formulated as a tablet, capsule or nasal formulation.


9. A process for preparing the compounds of formula I as defined in claim 1, which process comprises:

(A) alkylating a benzimidazole compound of the formula



15 wherein  $R_3$  is defined as above and  $R_2$  is other than hydroxy or amino, with a compound of the formula  $R_1X$  where  $R_1$  is defined as above and X is fluoro, chloro, bromo, or iodo, to provide the compounds of formula I where  $R_2$  is other than hydroxy or amino; or

20 (B) heating a compound of the formula




wherein  $R_1$  and  $R_3$  are defined as above, with formic acid or lactic acid, preferably in the presence of a mineral acid, to provide the compounds of formula I

30 wherein  $R_2$  is hydrogen or 1-hydroxyethyl; or

X-5513--(EPO)


-73-

(C) cyclizing a compound of the formula




wherein  $R_1$  and  $R_3$  are defined as above, with cyanogen.  
halide, to provide the compounds of formula I wherein  
 $R_2$  is amino; or

10 (D) alkylating a benzimidazole compound of  
the formula



wherein  $R_1$  and  $R_3$  are defined as above, with a  $C_1$ - $C_4$   
alkyl halide, to provide the compounds of formula I  
20 wherein  $R_2$  is  $C_1$ - $C_4$  alkylamino; or

(E) alkylating a benzimidazole compound of  
the formula



wherein  $R_1$  and  $R_3$  are defined as above, with methyl  
30 halide in the presence of a weak base, to provide the  
compounds of formula I wherein  $R_2$  is methylmercapto;  
or


AD ORIGINAL

X-5513-(EPO)

-74-

(F) acylating a benzimidazole compound of the formula


5



wherein  $R_1$  and  $R_3$  are defined as above, with a  $C_2-C_4$  anhydride, a mixed anhydride of formic and acetic anhydride, or a  $C_1-C_4$  acyl halide, to provide the compounds of formula I wherein  $R_2$  is  $C_1-C_4$  acylamino; or

(G) reacting a benzimidazole compound of the formula

20



wherein  $R_2$  and  $R_3$  are defined as above, with  $R_4R_5NH$ , where  $R_4$  and  $R_5$  are defined as above, and formaldehyde, to provide the compounds of formula I wherein  $R_1$  is  $R_4R_5NCH_2-$ ; or

30


BAD ORIGINAL




X-5513-(EPO)

-75-

(H) condensing a compound of the formula




wherein  $R_1$  and  $R_3$  are defined as above, with a  $\beta$ -keto ester of the formula



15 wherein  $n$  is 0-2, to provide the compounds of formula I wherein  $R_2$  is hydrogen and  $R_1$  is  $C_5$ - $C_7$  cycloalken-1-yl; or

(I) esterifying a benzimidazole compound of the formula



25 wherein  $R_1$  is defined as above, and  $R_2$  does not contain a hydroxy group, with an anhydride or acyl halide, to provide the compounds of formula I wherein  $R_3$  is  $C_2$ - $C_8$  alkanoyloxy, unsubstituted or substituted phenylacetoxy, or unsubstituted or substituted benzoyloxy; or

30


BAD ORIGINAL



X-5513-(EPO)

-76-

(J) reacting a benzimidazole compound of the formula




wherein  $R_1$ ,  $R_2$  and  $R_6$  are defined as above, with hydroxylamine, or its hydrochloride salt, hydrazine or  $C_1-C_4$  alkoxyamine, to provide the compounds of formula I wherein Z is hydroxyimino, hydrazono, or  $C_1-C_4$  alkoxyimino; or

(K) acylating a compound of formula I wherein Z is hydroxyimino with a  $C_1-C_4$  anhydride or a  $C_1-C_4$  acyl halide, to provide the compounds of formula I wherein Z is  $C_1-C_4$  acyloxyimino; or

(L) etherifying a compound of formula I wherein Z is hydroxyimino with a  $C_1-C_4$  alkyl halide, or alkylating the compound of formula I where  $R_3$  is  $R_6-C(=O)-$  with a  $C_1-C_4$  alkoxyamine, to provide the compounds of formula I wherein Z is  $C_1-C_4$  alkoxyimino; or

(M) dehydrating a benzimidazole compound of the formula




BAD ORIGINAL

X-5513-(EPO)

-77-

- wherein  $R_1$ ,  $R_2$  and  $R_6$  are defined as above, and one of  $R_7$  and  $R_8$  is hydrogen and the other of  $R_7$  and  $R_8$  is hydrogen,  $C_1$ - $C_6$  alkyl,  $-CN$ ,  $-CONH_2$ , or  $-CO_2$ -( $C_1$ - $C_4$  alkyl), with an acid, to provide the compounds of formula I wherein  $Z$  is  $C_1$ - $C_7$  alkylidene,  $=CHCN$ ,  $=CHCONH_2$ , or  $=CHCO_2$ -( $C_1$ - $C_4$  alkyl); or
- (N) reacting a benzimidazole compound of the formula



- 15 wherein  $R_1$ ,  $R_2$  and  $R_6$  are defined as above, with a halogenating agent, to provide the compounds of formula I wherein  $Z$  is  $=CHBr$ ,  $=CHCl$ ,  $=CBr_2$ ,  $=CCl_2$ , or  $=CBrCl$ ; or
- (O) resolving the benzimidazole compounds of formula I into its 5 and 6 isomers; or
- (P) resolving the benzimidazole compounds of formula I wherein  $Z$  is hydroxyimino,  $C_1$ - $C_4$  alkoxyimino,  $C_1$ - $C_4$  acyloxyimino, or hydrazono into its syn and anti isomers; or
- 25 (Q) resolving the benzimidazole compounds of formula I wherein  $Z$  is  $C_1$ - $C_7$  alkylidene,  $=CHBr$ ,  $=CHCl$ ,  $=CBr_2$ ,  $=CCl_2$ ,  $=CBrCl$ ,  $=CHCN$ ,  $=CHCONH_2$  or  $=CHCO_2$ -( $C_1$ - $C_4$  alkyl) into its cis and trans isomers; or
- 30 (R) salifying the compounds of formula I to form pharmaceutically acceptable salts.


X-5513-(P)

- 78 -

CLAIMS

1. A process for preparing a benzimidazole compound of the formula

5



10 wherein:

$R_1$  is  $C_1-C_8$  alkyl,  $C_2-C_8$  alkenyl,  $C_3-C_7$  cycloalkyl,  $C_5-C_7$  cycloalken-1-yl, 2-pyridyl, 2-thiazolyl, adamantyl, hydroxy-substituted  $C_1-C_8$  alkyl, unsubstituted or substituted phenyl, unsubstituted or substituted benzyl, or  $R_4R_5NCH_2-$ , where  $R_4$  and  $R_5$  are independently  $C_1-C_3$  alkyl or  $R_4$  and  $R_5$ , when taken together with the nitrogen atom to which they are attached, are pyrrolidino, piperidino, or morpholino;

15

$R_2$  is hydrogen, amino,  $C_1-C_4$  alkylamino, methylmercapto, hydroxy,  $C_1-C_4$  acylamino, or 1-hydroxyethyl;

20

$R_3$  is  $C_2-C_8$  alkanoyloxy, unsubstituted or substituted phenylacetoxo, unsubstituted or substituted benzoyloxy, or  $R_6C-\underset{Z}{\parallel}$ ;

25

$Z$  is oxygen, hydroxyimino,  $C_1-C_4$  alkoxyimino,  $C_1-C_4$  acyloxyimino, hydrazono,  $C_1-C_7$  alkylidene,  $=CHBr$ ,  $=CHCl$ ,  $=CBr_2$ ,  $=CCl_2$ ,  $=CBrCl$ ,  $=CHCN$ ,  $=CHCONH_2$ , or  $=CHCO_2(C_1-C_4 \text{ alkyl})$ ;

30




-79-

X-5513-(P)

$R_6$  is  $C_1$ - $C_7$  alkyl,  $C_3$ - $C_7$  cycloalkyl, ( $C_3$ - $C_7$  cycloalkyl)methyl, 2-( $C_3$ - $C_7$  cycloalkyl)ethyl, unsubstituted or substituted benzyl, unsubstituted or substituted phenyl; and


5  $R_3$  is at the 5 or 6 position,  
subject to the limitation that when  $R_2$  is hydroxy,  $R_1$  may only be  $C_5$ - $C_7$  cycloalken-1-yl; and the pharmaceutically acceptable salts thereof, which process comprises:

10 (A) alkylating a benzimidazole compound of the formula



wherein  $R_3$  is defined as above and  $R_2$  is other than hydroxy or amino, with a compound of the formula  $R_1X$  where  $R_1$  is defined as above and X is fluoro, chloro, 20 bromo, or iodo, to provide the compounds of formula I where  $R_2$  is other than hydroxy or amino; or

(B) heating a compound of the formula



30 wherein  $R_1$  and  $R_3$  are defined as above, with formic acid or lactic acid, preferably in the presence of




0111993

-80-

X-5513-(P)

a mineral acid, to provide the compounds of formula I wherein  $R_2$  is hydrogen or 1-hydroxyethyl; or  
(C) cyclizing a compound of the formula


5



10 wherein  $R_1$  and  $R_3$  are defined as above, with cyanogen halide, to provide the compounds of formula I wherein  $R_2$  is amino; or

(D) alkylating a benzimidazole compound of the formula


15



20

wherein  $R_1$  and  $R_3$  are defined as above, with a  $C_1-C_4$  alkyl halide, to provide the compounds of formula I wherein  $R_2$  is  $C_1-C_4$  alkylamino; or

(E) alkylating a benzimidazole compound of  
25 the formula



30


BAD ORIGINAL

- 81 -

X-5513-(P)


wherein  $R_1$  and  $R_3$  are defined as above, with methyl halide in the presence of a weak base, to provide the compounds of formula I wherein  $R_2$  is methylmercapto; or

- 5 (F) acylating a benzimidazole compound of the formula



- 15 wherein  $R_1$  and  $R_3$  are defined as above, with a  $C_2-C_4$  anhydride, a mixed anhydride of formic and acetic anhydride, or a  $C_1-C_4$  acyl halide, to provide the compounds of formula I wherein  $R_2$  is  $C_1-C_4$  acylamino; or

- 20 (G) reacting a benzimidazole compound of the formula



- 25 wherein  $R_2$  and  $R_3$  are defined as above, with  $R_4R_5NH$ , where  $R_4$  and  $R_5$  are defined as above, and formaldehyde, to provide the compounds of formula I wherein  $R_1$  is  $R_4R_5NCH_2-$ ; or

30


BAD ORIGINAL



-82-


X-5513-(P)

(H) condensing a compound of the formula



wherein  $R_1$  and  $R_3$  are defined as above, with a  $\beta$ -keto ester of the formula

10




15

wherein  $n$  is 0-2, to provide the compounds of formula I wherein  $R_2$  is hydrogen and  $R_1$  is  $C_5$ - $C_7$  cycloalken-1-yl; or

(I) esterifying a benzimidazole compound  
20 of the formula

25




wherein  $R_1$  is defined as above, and  $R_2$  does not contain a hydroxy group, with an anhydride or acyl halide, to provide the compounds of formula I wherein  $R_3$

30

X-5513-(P)

is C<sub>2</sub>-C<sub>8</sub> alkanoyloxy, unsubstituted or substituted phenylacetoxy, or unsubstituted or substituted benzoyloxy; or

(J) reacting a benzimidazole compound of  
5 the formula



10

wherein R<sub>1</sub>, R<sub>2</sub> and R<sub>6</sub> are defined as above, with hydroxylamine, or its hydrochloride salt, hydrazine or C<sub>1</sub>-C<sub>4</sub> alkoxyamine, to provide the compounds of  
15 formula I wherein Z is hydroxyimino, hydrazono, or C<sub>1</sub>-C<sub>4</sub> alkoxyimino; or

(K) acylating a compound of formula I wherein Z is hydroxyimino with a C<sub>1</sub>-C<sub>4</sub> anhydride or a C<sub>1</sub>-C<sub>4</sub> acyl halide, to provide the compounds of formula I  
20 wherein Z is C<sub>1</sub>-C<sub>4</sub> acyloxyimino; or

(L) etherifying a compound of formula I wherein Z is hydroxyimino with a C<sub>1</sub>-C<sub>4</sub> alkyl halide, or alkylating the compound of formula I where R<sub>3</sub> is R<sub>6</sub>-C(=O)- with a C<sub>1</sub>-C<sub>4</sub> alkoxyamine, to provide the com-  
25 pounds of formula I wherein Z is C<sub>1</sub>-C<sub>4</sub> alkoxyimino; or

30


0111993

- 84 -

X-5513-(P)

(M) dehydrating a benzimidazole compound  
of the formula


5



10 wherein  $R_1$ ,  $R_2$  and  $R_6$  are defined as above, and one  
of  $R_7$  and  $R_8$  is hydrogen and the other of  $R_7$  and  $R_8$   
is hydrogen,  $C_1$ - $C_6$  alkyl,  $-CN$ ,  $-CONH_2$ , or  $-CO_2$ -( $C_1$ - $C_4$   
alkyl), with an acid, to provide the compounds of  
formula I wherein Z is  $C_1$ - $C_7$  alkylidene,  $=CHCN$ ,  
15  $=CHCONH_2$ , or  $=CHCO_2$  ( $C_1$ - $C_4$  alkyl); or

(N) reacting a benzimidazole compound of  
the formula

20



25 wherein  $R_1$ ,  $R_2$  and  $R_6$  are defined as above, with a  
halogenating agent, to provide the compounds of  
formula I wherein Z is  $=CHBr$ ,  $=CHCl$ ,  $=CBr_2$ ,  $=CCl_2$ ,  
or  $=CBrCl$ ; or

30

BAD ORIGINAL

0111993

- 85 -

X-5513-(P)

(O) resolving the benzimidazole compounds of formula I into its 5 and 6 isomers; or

(P) resolving the benzimidazole compounds of formula I wherein Z is hydroxyimino, C<sub>1</sub>-C<sub>4</sub> alkoxyimino, C<sub>1</sub>-C<sub>4</sub> acyloxyimino, or hydrazono into its syn and anti isomers; or

(Q) resolving the benzimidazole compounds of formula I wherein Z is C<sub>1</sub>-C<sub>7</sub> alkylidene, =CHBr, =CHCl, =CBr<sub>2</sub>, =CCl<sub>2</sub>, =CBrCl, =CHCN, =CHCONH<sub>2</sub> or =CHCO<sub>2</sub>(C<sub>1</sub>-C<sub>4</sub> alkyl) into its cis and trans isomers; or

(R) salifying the compounds of formula I to form pharmaceutically acceptable salts.

2. The process of claim 1 (J) for preparing 1-(t-butyl)-6-( $\alpha$ -hydroxyiminobenzyl)benzimidazole which comprises reacting 1-(t-butyl)-6-benzoylbenzimidazole with hydroxylamine hydrochloride.

3. The process of claim 1 (J) for preparing 1-cyclohexyl-2-amino-6-( $\alpha$ -hydroxyiminobenzyl)benzimidazole which comprises reacting 1-cyclohexyl-2-amino-6-benzoylbenzimidazole with hydroxylamine hydrochloride.

4. The process of claim 1 (J) for preparing 1-cyclohexyl-2-amino-6-( $\alpha$ -hydroxyimino-4'-methoxybenzyl)benzimidazole which comprises reacting 1-cyclohexyl-2-amino-6-(4'-methoxybenzoyl)benzimidazole with hydroxylamine hydrochloride.

5. The process of claim 1 (J) for preparing 1-isopropyl-2-amino-6-( $\alpha$ -hydroxyiminobenzyl)benzimidazole which comprises reacting 1-isopropyl-2-amino-6-benzoylbenzimidazole with hydroxylamine hydrochloride.

DAD ORIGINAL

X-5513-(P)

6. The process of claim 1 (J) for preparing 1-phenyl-2-amino-6-( $\alpha$ -hydroxyiminobenzyl)benzimidazole which comprises reacting 1-phenyl-2-amino-6-benzoylbenzimidazole with hydroxylamine hydrochloride.

5 7. The process of claim 1 (M) for preparing 1-isopropyl-2-amino-6-(1-phenyl-1-propenyl)benzimidazole which comprises reacting 1-isopropyl-2-amino-6-( $\alpha$ -hydroxy- $\alpha$ -ethylbenzyl)benzimidazole with formic acid.

10 8. The process of claim 1 (N) for preparing 1-isopropyl-2-amino-6-(1-phenyl-2-bromoethenyl)benzimidazole which comprises reacting 1-isopropyl-2-amino-6-(1-phenylethenyl)benzimidazole with N-bromosuccinimide.

15 9. The process of claim 1 (M) for preparing 1-isopropyl-2-amino-6-(1-phenyl-2-cyanoethenyl)benzimidazole which comprises reacting 1-isopropyl-2-amino-6-( $\alpha$ -hydroxy- $\alpha$ -cyanomethylbenzyl)benzimidazole with formic acid.

20 10. The process of claim 1 (M) for preparing 1-phenyl-2-amino-6-(1-phenyl-2-cyanoethenyl)benzimidazole which comprises reacting 1-phenyl-2-amino-6-( $\alpha$ -hydroxy- $\alpha$ -cyanomethylbenzyl)benzimidazole with formic acid.

25 11. The process of claim 1 (M) for preparing 3-(1-isopropyl-2-aminobenzimidazol-6-yl)-3-phenyl-2-propenamide which comprises reacting 1-isopropyl-2-amino-6-[ $\alpha$ -hydroxy- $\alpha$ -bis(trimethylsilyl)acetamido]benzylbenzimidazole with ammonium chloride.

30 12. A benzimidazole of formula I or a pharmaceutically acceptable salt thereof, whenever prepared by a process according to any one of claims 1-11.



12

**EUROPEAN PATENT APPLICATION**

21 Application number: 83305611.2

22 Date of filing: 22.09.83

51 Int. Cl.<sup>3</sup>: **C 07 D 235/30, C 07 D 235/06,**  
**C 07 D 235/28, C 07 D 235/26,**  
**C 07 D 235/12, C 07 D 401/04,**  
**C 07 D 417/04, A 61 K 31/415,**  
**A 61 K 31/425, A 61 K 31/44**

30 Priority: 27.09.82 US 424784

43 Date of publication of application: 27.06.84  
Bulletin 84/26

64 Designated Contracting States: **AT BE CH DE FR GB IT**  
**LI LU NL SE**

83 Date of deferred publication of search  
report: 25.07.84 Bulletin 84/30

71 Applicant: **ELI LILLY AND COMPANY, 307, East McCarty**  
**Street, Indianapolis Indiana 46285 (US)**

72 Inventor: **Spitzer, Wayne Alfred, 5501 Moller Road,**  
**Indianapolis Indiana 46254 (US)**

74 Representative: **Crowther, Terence Roger et al, Erl Wood**  
**Manor, Windlesham Surrey GU20 6PH (GB)**

54 Improvements in or relating to benzimidazoles.

57 Certain N-substituted benzimidazoles, which are potent antiviral agents, are disclosed. The compounds are prepared by reacting the corresponding keto derivative with an alkylating agent or by cyclizing the corresponding o-phenylenediamine. Pharmaceutical formulations containing such compounds and a method of treating viral infections are provided.





European Patent  
Office

# EUROPEAN SEARCH REPORT

0111993  
Application Number

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	EP 03 30 5611 CLASSIFICATION OF THE APPLICATION (Int. Cl. 3)
A	DE-A-2 310 076 (SQUIBB)		C 07 D 235/30 C 07 D 235/06 C 07 D 235/28 C 07 D 235/26
A	GB-A-1 111 557 (SKF)		C 07 D 235/12 C 07 D 401/04 C 07 D 417/04
A	FR-A-1 384 313 (SCHERING)		A 61 K 31/415 A 61 K 31/425 A 61 K 31/44
A	US-A-4 230 868 (PAGET et al.)		
A	EP-A-0 015 339 (ELI LILLY)		
			TECHNICAL FIELDS SEARCHED (Int. Cl. 3)
			C 07 D 235/00 C 07 D 401/00 C 07 D 417/00 A 61 K 31/00
The present search report has been drawn up for all claims			
Place of search THE HAGUE		Date of completion of the search 08-02-1984	Examiner DE BUYSER I.A.F.
<b>CATEGORY OF CITED DOCUMENTS</b>			
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document	

EPO Form 1503, 03.82

BAD ORIGINAL



**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☒ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☒ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**